Polymorphic short tandem repeats make widespread contributions to blood and serum traits

Jonathan Margoliash[1], Shai Fuchs[2], Yang Li[1,3], Xuan Zhang[3], Arya Massarat[4], Alon Goren[3,*], Melissa Gymrek[1,3,*]

[1]Department of Computer Science and Engineering, University of California San Diego, La Jolla, CA

[2]Pediatric Endocrine and Diabetes Unit, Sheba Medical Center, Edmond and Lily Safra Children's Hospital, Tel-Hashomer, Israel.

[3]Department of Medicine, University of California San Diego, La Jolla, CA

[4]Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA

*Correspondence should be addressed to agoren@ucsd.edu and mgymrek@ucsd.edu.

Abstract

Short tandem repeats (STRs), genomic regions each consisting of a sequence of 1-6 base pairs repeated in succession, represent one of the largest sources of human genetic variation. However, many STR effects are not captured well by standard genome-wide association studies (GWAS) or downstream analyses that are mostly based on single nucleotide polymorphisms (SNPs). To study the involvement of STRs in complex traits, we imputed genotypes for 445,720 autosomal STRs into genotype array data from 408,153 White British UK Biobank participants and tested for association with 44 blood and serum biomarker phenotypes. We used two fine-mapping methods, SuSiE and FINEMAP, to identify 119 high-confidence STR-trait associations across 93 unique STRs predicted as causal variants under all fine-mapping settings tested. Using these results, we estimate that STRs account for 5.2-7.6% of causal variants identifiable from GWAS signals for these traits. Our high confidence STR-trait associations implicate STRs in some of the strongest hits for multiple phenotypes, including a CTG repeat in *APOB* associated with circulating apolipoprotein B levels, a CGG repeat in the promoter of *CBL* associated with multiple platelet traits and a poly-A repeat in *TAOK1* associated with mean platelet volume. Replication analyses in additional population groups and orthogonal expression data further support the role of a subset of the candidate STRs we identify. Together, our study suggests that polymorphic tandem repeats make widespread contributions to complex traits, provides a set of stringently selected candidate causal STRs, and demonstrates the need to routinely consider a more complete view of human genetic variation in GWAS.

Introduction

Genome-wide association studies (GWAS) have become an indispensable tool for identifying which genes and non-coding regions in the genome influence complex human traits. While GWAS routinely identify tens to hundreds of genomic regions associated with individual traits, biological interpretation of GWAS results remains challenging[1]. A major limitation is that typical GWAS pipelines only consider a subset of common genetic variants. The majority of GWAS have been based on common single nucleotide polymorphisms (SNPs) and short insertions or deletions (indels) either genotyped using microarrays or imputed from population reference databases based on whole genome sequencing (WGS) data. However, detailed follow-up of individual GWAS signals has often revealed complex variants that were absent from the original analysis, such as repeats[2,3] or structural variants[4,5], to be the causal drivers of those signals. Indeed, a recent study showed that polymorphic protein-coding variable number tandem repeats (VNTRs) are likely causal drivers of some of the strongest GWAS signals identified to date for multiple traits[2].

Short tandem repeats (STRs) are a type of complex variant that consist of repeat units between 1-6bp duplicated many times in succession. Over one million STRs occur in the human genome[6], each spanning from tens to thousands of base pairs. STRs undergo frequent mutations resulting in gain or loss of repeat units[7], with per-locus mutation rates several orders of magnitude higher than average rates for SNPs[8] or indels[9]. Large repeat expansions at STRs are known to result in Mendelian diseases such as Huntington's disease, muscular dystrophies, hereditary ataxias and intellectual disorders[10,11]. Further, recent evidence suggests that more modest but highly prevalent variation at multi-allelic non-coding STRs can also be functionally relevant. We and others have found associations between STR length and both gene expression[3,12,13] and splicing[14,15]. The impact of non-coding STRs on gene expression is hypothesized to be mediated by a variety of mechanisms including modulating nucleosome positioning[16], altering methylation[12,17], affecting transcription factor recruitment[3] and impacting the formation of non-canonical DNA[18,19] and RNA[20,21] secondary structures. Together, these suggest that STRs potentially play an important role in shaping complex traits in humans.

Despite this potential, STRs are not well-captured by current GWAS. Because STRs are not directly genotyped by microarrays and are challenging to analyze from WGS, STRs have been largely excluded from widely used reference haplotype panels[22–24] and downstream GWAS analyses. While some STRs are in high linkage disequilibrium (LD) with nearby SNPs, many

66 highly multi-allelic STRs can only be imperfectly tagged by individual common SNPs, which are
67 typically bi-allelic. Thus effects driven by variation in repeat length have likely not been fully
68 captured, especially at those highly polymorphic STRs which cannot be well approximated by a
69 bi-allelic indel or well-tagged by bi-allelic SNPs.

70 Recent technological advances can now enable incorporation of STRs into GWAS. We and others
71 have created a variety of bioinformatic tools to genotype STRs directly from WGS by statistically
72 accounting for the noise inherent in STR sequencing[6,25–29]. We previously used these tools to
73 develop a reference haplotype panel consisting of both SNP and STR genotypes that allows for
74 imputation of STRs from genotype array data[30] in samples for which WGS is unavailable. In that
75 study we found that all but the most highly polymorphic STRs are amenable to imputation in
76 European cohorts, with an average per-locus imputation concordance of 97% with genotypes
77 obtained from WGS.

78 Here, we leverage our SNP-STR reference haplotype panel to impute genome-wide STRs into
79 SNP array data from 408,153 White British individuals obtained from the UK Biobank (UKB) for
80 which deep phenotype information is available[31]. Whereas a recent publication studied the effects
81 of protein-coding VNTRs (118 total VNTRs with repeat units of 7+ base pairs; total length of up
82 to several kilobases) on complex traits[2], our study focuses on a distinct set of repeats (namely
83 445,720 STRs with repeat units of 1bp to 6bp) which are mostly non-coding. We test for
84 association between imputed STR lengths and 19 blood cell count and 25 biomarker traits. These
85 traits provide multiple advantages: they are broadly and reliably measured, continuous, highly
86 polygenic and have variants with relatively large effect sizes, thus enabling well-powered
87 association testing.

88 We performed fine-mapping on these associations and estimate that STRs account for 5.2-7.6%
89 of signals identified by GWAS for the traits we studied. We observed that fine-mapping results in
90 some instances are substantially influenced by the choice of fine-mapper, and additionally are
91 moderately sensitive to data-processing choices and fine-mapper instabilities, and thus require
92 careful interpretation. After restricting to the signals which were consistently fine-mapped across
93 multiple fine-mappers and fine-mapping settings, we identified 93 unique STRs strongly predicted
94 to be causal for at least one trait. We highlight multiple STRs in this set which we predict contribute
95 to some of the strongest hits for many traits, including apolipoprotein B, platelet crit and mean
96 platelet volume. Overall, our study demonstrates the widespread role of polymorphic tandem

97 repeats and the need to consider a broad range of variant types in GWAS and downstream
98 analyses such as fine-mapping.

99 Results

100 *Performing genome-wide STR association studies in 44 traits*

101 We imputed genotypes for 445,720 autosomal STRs into phased genotype array data from
102 408,153 White British individuals from the UKB using Beagle[32] in combination with our published
103 SNP-STR reference haplotype panel[30] (**Methods**; **Fig. 1a**; **Supplementary Fig. 1**; **URLs**). We
104 find that this imputation yields broadly similar genotypes to WGS (see below). Compared to
105 common SNPs, which are typically bi-allelic, many of the imputed STRs are highly multi-allelic
106 (**Fig. 1b**). We tested STRs for association with 44 quantitative blood cell count and other
107 biomarker traits (**Supplementary Table 1**) for which phenotype information was available for
108 between 304,658-335,585 genetically unrelated subsets of individuals. To facilitate this and other
109 STR association studies, we developed associaTR (**URLs**), an open-source software package
110 for identifying associations between STR lengths (as measured by the number of repeat units)
111 and phenotypes.

112 For each STR-trait pair, we used associaTR to test for a linear association between STR dosage
113 (the sum of the imputed allele length dosages of both chromosomes) and the measured trait value
114 (**Fig. 1c-d**). For comparison, we used plink[33] to perform similar association tests using 70,698,786
115 SNP and short indel variants that were imputed into the same individuals. For all associations
116 (STR, SNP and indel), we included as covariates SNP-genotype principal components, sex, and
117 age (**Methods**). Additional covariates were included on a per-trait basis (**Supplementary Table**
118 **1**). We compared the output of our SNP analysis pipeline to previous results reported by Pan
119 UKBB[34] and found that our pipeline produced similar results, although had slightly weaker p-
120 values overall. (**Supplementary Fig. 2**).

121 We then compared signals identified by SNPs and indels to those identified by STRs. For each
122 trait we defined peaks as non-overlapping 250kb intervals centered on the lead genome-wide
123 significant variant (a SNP, indel or STR with $p<5e-8$) in that interval (**Methods**). We identified an
124 average of 389 peaks per trait, with blood cell count traits generally more polygenic than other
125 biomarkers (**Fig. 1e**). Of these peaks, 65.9% contained both a significant STR and a significant
126 SNP or indel, 32.5% contained only significant SNPs or indels, and 1.7% contained only
127 significant STRs. The majority of strong peaks (containing any variant with $p<1e-100$) were

identified by both STRs and SNPs and/or indels, in that they contain both an STR and a SNP or indel with p<1e-80. No new strong peaks were identified only by STRs (**Fig. 1f**), which is unsurprising given that SNP and indel genotypes were used to impute the STRs. Overall, p-values of the lead SNP or indel and lead STR were similar for most peaks. Thus, we focused on fine-mapping to determine which variants might be causally driving the identified signals.



Figure 1: Genome-wide association tests identify STRs, SNPs and indels associated with blood and biomarker traits in the UKB. (a) Schematic overview of this study. STRs are imputed into phased hard-called variants obtained from genotype arrays. GWAS is performed on SNPs and STRs in parallel. Regions with significant signals are identified and then fine-mapped by two independent methods each under multiple scenarios, resulting in candidate causal STRs. **(b) Distribution of the number of common alleles at each imputed STR.** Common alleles are defined as alleles with estimated frequency ≥1% (**Methods**). For clarity we omitted from this figure the 237 imputed STRs with only a single imputed allele with frequency ≥1%. **(c-d) Representative association results.** Manhattan plots are shown for phenotypes **(c)** total bilirubin (an example moderately polygenic trait) and **(d)** platelet count (an example highly polygenic trait). Large diamonds represent the lead variants (pruned to include at most one lead variant per 10Mb for visualization). -log10 p-values are truncated at 100. Blue=SNPs and indels; orange=STRs. **(e) Summary of signals identified for each trait.** Bars show the number of peaks per phenotype. Blue denotes peaks only containing genome-

wide significant SNPs and indels, purple denotes peaks containing both significant SNPs/indels and STRs. The number of peaks only containing significant STRs is too small to be visible in this display. **(f) Comparison between lead SNP and indel and STR p-values at each peak.** If there are no STRs in a peak, the y coordinate is set to zero (same for SNPs and indels). p-values are capped at 1e-300, the maximum precision of our pipeline. The shade represents the number of peaks falling at each position on the graph. The bottom left tile (which only contains peaks whose lead SNP/indel and STR variants fall in the least significant bin) has been removed so as not to not skew the scale of the color bar.

Fine-mapping suggests 5.2-7.6% of significant signals are driven by STRs

We applied statistical fine-mapping to identify candidate causal variants that may be driving the GWAS signals detected above. We used two fine-mapping methods: SuSiE[35] and FINEMAP[36]. These methods differ in their modeling assumptions and thus provide partially orthogonal predictions. For each trait we divided its genome-wide significant variants (SNPs, indels and STRs) and nearby variants into non-overlapping regions of at least 250kb (**Methods**). This resulted in 14,491 fine-mapping trait-regions (**Supplementary Table 2**), with some trait-regions containing multiple nearby peaks. To compare outputs between fine-mappers in downstream analyses, we defined the causal probability (CP) of each variant to be a number between 0 and 1 that indicates the variant's chance of causality. For FINEMAP we defined a variant's CP to be the FINEMAP posterior inclusion probability (PIP) calculated for that variant. For SuSiE we defined a variant's CP to be the maximal SuSiE alpha value for that variant across pure credible sets in the region (**Supplementary Figs. 3-4**). We explain the rationale behind this choice in **Supplementary Note 1**.

We used two approaches to study the contribution of STRs vs. SNPs and indels to fine-mapped signals. First, we focused on the genome-wide significant variants (STR, SNP, or indel) with CP ≥ 0.8. (These accounted for a minority of the total 21,045 pure signals detected by SuSiE and the total 33,756 signals detected by FINEMAP). SuSiE identified 4,494 such variants and FINEMAP identified 5,170. Of these, 7.4% (range 1.3-13.0% across traits; SuSiE) and 7.6% (range 1.4-14.0%; FINEMAP) are STRs. Among the subset of variants identified by both methods (3,961), 5.4% (range 1.0-11.1%) are STRs. Second, we considered the sum of CPs from all genome-wide significant variants, thereby taking into account the many signals which were not resolved to a single variant. STRs make up 5.2% (range 1.1-6.8%) of the total SuSiE CP sum and 7.4% (range 2.9-9.0%) of the total FINEMAP CP sum. A potential limitation of this second metric is that variants with small CPs (CP ≤ 0.1) represent a large fraction (29.3% for SuSiE, 35.1% for FINEMAP) of these totals (**Supplementary Fig. 5**). Additionally, our results below suggest that a sizable subset of variant CPs are either discordant between fine-mappers or unstable, particularly for STRs (**Supplementary Notes 2-3**), impacting the totals in both metrics. Nevertheless, the results above

180 suggest that between 5.2-7.6% of causal variants identifiable from GWAS can be attributed to an
181 STR, regardless of the fine-mapping method or metric used. This is in line with the total
182 percentage of non-major alleles per person and roughly half the total percentage of base pair
183 variation per person accounted for by STR lengths compared to other variant types in our study
184 (**Supplementary Table 3**). We report all 511 genome-wide significant STR associations across
185 409 distinct STRs with either FINEMAP or SuSiE CP ≥ 0.8 in **Supplementary Table 4**, and a
186 subset of those which pass more stringent thresholding in **Supplementary Table 5** (see below).

187 To evaluate the reliability of our approach for determining the relative contributions of STRs vs
188 SNPs and indels, we performed fine-mapping simulation analyses assuming a simple additive
189 model. We used two strategies for simulating phenotypes, in each case simulating only causal
190 SNPs and indels, and assessed to what extent STRs were incorrectly identified by SuSiE or
191 FINEMAP as contributing to the underlying signals. For the first strategy, we chose between one
192 and three causal SNPs or indels at random, weighting by minor allele frequencies, for a total of
193 1644 simulations. For the second, we chose causal variants to be those indicated by SuSiE as
194 being potentially causal for a representative trait (platelet count), in an attempt to more closely
195 capture properties of truly causal variants during simulation, for a total of 1374 simulations. These
196 simulations procedures and rationales are described in more detail in the **Methods**,
197 **Supplementary Table 6** and **Supplementary Fig. 6**.

198 When simulating from one to three randomly chosen causal SNPs or indels, of genome-wide
199 significant variants that SuSiE or FINEMAP assigned CP ≥ 0.8, between 0% and 0.46% were
200 STRs. In contrast, using phenotypes simulated from the second strategy, between 1.4% and 3.2%
201 were STRs (**Supplementary Table 7**). Across all genome-wide significant variants, of the total
202 CP assigned by SuSiE or FINEMAP, 0.50% to 0.95% and 3.1% to 3.2% were assigned to STRs
203 in the first and second simulation strategies, respectively (**Supplementary Table 8**). These
204 numbers are uniformly lower than the 5.2-7.6% STR contributions identified above. This suggests
205 that if the 44 traits studied here have genetic architectures similar to the phenotypes we simulated,
206 the results above are unlikely to be fully explained by systematic bias of these fine-mappers in
207 favor of STRs. However, we expect there are complexities to the genetic architecture of blood
208 traits that are not captured by our simulations, and we cannot rule out the possibility that they
209 could result in such bias. These results also suggest that some of the fine-mapped STRs may be
210 false positives, and thus that our estimates of STR contributions could be somewhat inflated. On
211 the other hand, we also observed that a large fraction (66-81%) of simulated causal SNPs and
212 indels are not assigned CP ≥ 0.8 by fine-mapping, and we see a similar lack of sensitivity in limited

213 simulations performed with causal STRs (**Supplementary Table 7**). We expect this low sensitivity
214 is a greater source of uncertainty regarding the relative contribution of each variant type than the
215 false positive rates reported here.

216 We evaluated imputation quality at the 409 STRs in **Supplementary Table 4** by comparing
217 imputed genotypes to genotypes obtained from recently released WGS data for 200,025 UKB
218 individuals. At each locus, we computed the Pearson r^2 between length dosages from imputation
219 and summed lengths from WGS hard-calls, in addition to other per-locus metrics (**Supplementary**
220 **Table 4**). For 78.7% of these STRs, per-locus r^2 values are greater than 0.9 and for 92.7% they
221 are greater than 0.8. Other measurements of imputation concordance perform comparably well
222 (**Supplementary Fig. 7; Methods**). Overall, they suggest that fine-mapping results from imputed
223 data are unlikely to systematically differ from fine-mapping of hard-called genotypes for these loci.
224 Unless otherwise stated, all results reported below are based on imputed genotypes.

225 ***Identifying and characterizing confidently fine-mapped STRs***

226 We performed additional analyses to identify a high confidence set of causal STR candidates.
227 First, we noticed that while SuSiE and FINEMAP tended to output similar results, they assigned
228 highly discordant CPs to a subset of variants (**Supplementary Note 2**; **Supplementary Figs. 8-**
229 **10**). Thus we conservatively restricted our follow-up analyses to the 167 candidate STR
230 associations with association p-values < 1e-10 and with CP ≥ 0.8 in both FINEMAP and SuSiE.
231 Second, to confirm that the default fine-mapping settings did not appreciably dictate our results,
232 we reran SuSiE and FINEMAP under a range of alternative settings (**Methods**), including using
233 best-guess STR genotypes instead of dosages and varying the prior distribution of effect sizes.
234 These additional fine-mapping runs tended to produce concordant results, but again for a subset
235 of STRs, produced highly inconsistent CPs (**Supplementary Figs. 11-14**), which we mostly
236 attribute to imputation uncertainty and FINEMAP instability (**Supplementary Note 3**). Thus, we
237 further restricted to the 118 (70.7%) of the 167 STR-trait associations which also maintained CP
238 ≥ 0.8 across these additional fine-mapping runs. We refer to the STR-trait associations meeting
239 these criteria as confidently fine-mapped STR associations. Lastly, we added an association with
240 an STR in the *APOB* gene to this set as this association only failed to meet the above criteria
241 because the STR was simultaneously represented in both our STR reference panel and in the
242 SNP and indel set generated by the UKB team (**Supplementary Note 4**). In sum, we were left
243 with 119 confidently fine-mapped STR-trait associations corresponding to 93 distinct STRs, which
244 we display in **Fig. 2** and **Supplementary Table 5**.

245 We evaluated these fine-mapping results by measuring their replication rates in populations
246 besides White British individuals, with the expectation that causal associations will replicate at
247 higher frequencies in other populations than non-causal associations due to having common
248 biological functionality. The UKB includes self-identified groups of 8,043 Black, 7,952 South
249 Asian, 1,568 Chinese, 12,957 Irish and 16,051 Other White participants that passed quality
250 control, with about 40% of each population having WGS data (**Methods**). Using that WGS data
251 we validated the imputed genotypes of those populations for the STRs in **Supplementary Table**
252 **4** and found that 78.2% and 93.9% of per-locus dosage r^2 values are greater than 0.8 and 0.6 in
253 the South Asian population, respectively, 45.5% and 84.8% in the Black population, and 64.3%
254 and 84.8% in the Chinese population (**Supplementary Fig. 7**). These metrics are weaker in the
255 non-White populations; this is expected given the largely European origin of our reference
256 haplotype panel. Nevertheless, our results suggest imputed genotypes are sufficiently accurate
257 across these groups for downstream analysis.

258 For each of these populations we performed follow-up STR association testing. Specifically, for
259 each trait, for each fine-mapping region for that trait identified among White British individuals, we
260 tested each STR in that region for association with that trait in each of the other populations
261 (**Supplementary Table 9**; data for individual loci in **Supplementary Tables 4** and **5**). As
262 expected, signals replicate at a higher rate in groups most closely related to our discovery cohort
263 (i.e. Irish and Other White). Encouragingly, fine-mapped associations replicate at higher rates
264 than non-fine-mapped associations in the Black, South Asian, and Chinese populations, even
265 after stratifying by the discovery p-value (**Fig. 3**, **Supplementary Fig. 15**). To quantitatively
266 measure this trend, for each population we fit a logistic regression model using whether signals
267 replicated in that population as the outcome, the fine-mapping status of those associations as the
268 independent variable, and their $-\log_{10}$(p-value) in the discovery cohort as a covariate
269 (**Supplementary Table 10)**. This analysis further supports the conclusion that fine-mapped
270 associations replicate at higher rates. Additionally, the model consistently predicts that confidently
271 fine-mapped STR associations replicate at higher rates than STR associations fine-mapped by
272 either fine-mapper alone, although only a subset of those predictions reached nominal
273 significance, likely due to the small number of fine-mapped STR associations.

274 Next, we sought to characterize the set of confidently fine-mapped STRs. This set contains 62
275 poly-A repeats, 11 poly-AC, 5 poly-CCG, and 15 repeats with other units. Twelve of these STRs
276 overlap coding or untranslated regions (UTRs) (**Table 1**; **Supplementary Table 11;** the two
277 protein-coding repeats are further described in **Supplementary Note 4**; **Supplementary Fig. 16**).

278 Compared to all genome-wide significant STRs, confidently fine-mapped STRs were more likely
279 to be exonic trinucleotide STRs, in 5' UTR regions or in genes that are not protein-coding (two-
280 sided two-sample test of difference between proportions p=2e-26, 1e-3 and 2e-4 respectively).
281 No other annotation categories that we tested showed significant enrichment or depletion after
282 multiple hypothesis correction, likely due to low power arising from the small number of confidently
283 fine-mapped STRs (**Methods**; **Supplementary Fig. 17**). Lastly, we observed that 18 of these
284 confidently fine-mapped STRs are significant *cis* expression quantitative trait loci (QTLs) and 12
285 are significant *cis* DNA methylation QTLs in the Genotype-Tissue Expression (GTEx) dataset[37]
286 (**Fig. 2; Supplementary Tables 12-14**; **Supplementary Fig. 18**; **Methods**). We note that the
287 expression and methylation analyses were underpowered because of low sample sizes,
288 particularly for relevant tissue types (e.g. kidney, liver).

STR coordinate (hg19 chr:pos)	Reference allele	Repeat unit	Trait	Association p-value	Association Z-score	Gene (annotation)	Transcription direction
1:204527033	$(TAA)_9$	AAT	platelet crit	5.76e-17	-8.37	*MDM4* (3' UTR)	+
2:21266752	$(CAG)_6(CGCAGGCAG)[CGC(CAG)_2]_2CGC$	CTG (poly-leucine)	Apolipo-protein B	1.37e-279	-35.76	*APOB* (Coding)	-
2:106510441	$(AC)_6GTG(CA)_{10}C(TA)_7T$	AC	mean platelet volume	6.93e-29	-11.15	*NCK2* (3' UTR)	+
2:111878544	$(CGC)(CGCTGC)_2(CGC)_{13}C$	CCG	eosinophil count	4.96e-58	+16.06	*BCL2L11* (5' UTR)	+
			eosinophil percent	5.88e-75	+18.32		
2:204311891	$T_4CT_4CT_3CT_{18}$	T	IGF-1	3.97e-11	-6.61	*ABI2* (3' UTR*) ENST00000295851.10 (1)	+
6:90121977	$(TC)_7$	TC	cystatin C	1.24e-16	+8.28	*RRAGD* (3' UTR)	-
11:119077000	$(CGG)_{11}C$	CGG	mean sphered cell volume	6.88e-16	-8.07	*CBL* (5' UTR*) ENST00000634586.1 (5)	+
			platelet count	3.77e-83	+19.32		
			platelet crit	6.07e-103	+21.55		
15:40312923	T_{16}	T	red blood cell count	2.27e-20	+9.25	*EIF2AK4* (Not protein coding*) ENST00000558743.1 (2)	+
16:67229794	$(CAG)_{13}(CAA)(CAG)(TAA)(CAG)_3$	AGC (poly-serine)	mean sphered cell volume	3.07e-23	+9.93	*E2F4* (Coding)	+
			red blood cell count	1.08e-13	-7.43		
			mean corpuscular haemoglobin	2.83e-23	+9.94		
			mean corpuscular volume	9.27e-26	+10.49		
17:30469471	$(CCG)_{16}CC$	CCG	red blood cell distribution width	6.57e-13	+7.19	*RHOT1* (5' UTR)	+
17:33871548	T_{17}	A	mean platelet volume	4.30e-62	-16.63	*SLFN14* (3' UTR)	-
20:32971954	A_{20}	A	shbg	6.37e-15	-7.80	Y RNA ENST00000364628.1 (3)	-

Table 1: Confidently fine-mapped STRs are identified in coding regions and untranslated regions (UTRs). Imputed alternate alleles and rsIDs are provided in **Supplementary Table 11.** Repeat units here are calculated as described in the **Methods**, except that they are required to be on the strand in the direction of transcription of the overlapping gene. We denote with asterisks the three STRs in this list which only appear in non-canonical transcripts

294 for their genes from Ensembl release 106. Additionally, two STRs in this list only appear in transcripts or genes which
295 are not protein coding. For all those STRs, we provide Ensembl transcript numbers followed by parentheses containing
296 the Ensembl transcript support level, a number from 1 to 5, with 1 being the highest level of evidence and 5 being the
297 lowest. Additional analysis and discussion of the potential impact of the protein-coding repeats in *APOB* and *E2F4* are
298 given in **Supplementary Note 4**.

299



Figure 2: STRs are confidently fine-mapped to causally impact many traits. Only STRs with at least one confidently fine-mapped association are shown. Each triangle represents an STR-trait association with association p-value < 1e-10. Black=confidently fine-mapped, red-brown=CP ≥ 0.8 in either initial FINEMAP or SuSiE run, light-tan=all other associations with p-values < 1e-10. Triangle direction (up or down) indicates the sign of the association between STR length and the trait. Triangle size scales with association p-value. Similar traits are grouped on the x-axis by white and light-grey bands. STRs are grouped on the y-axis according to the traits they were confidently fine-mapped to.

STRs are labeled by the genes they reside in (protein coding genes preferred) or by chromosomal location and the nearest gene for intergenic STRs. *CCDC26* and *TFDP2* each contain two confidently fine-mapped STRs and appear twice. Light blue rows indicate (from left to right): whether each STR is associated with expression of a nearby gene in the GTEx cohort (adjusted p<0.05; **Supplementary Table 12**), associated with the methylation of a nearby CpG island (**Supplementary Table 14**), replicates with the same direction of effect in other populations (adjusted p<0.05; **Methods**), repeat unit, and the number of common alleles for each STR (as defined in **Fig. 1**; see scale beneath). Additionally, we mark the STRs in *TAOK1* and *RHOT1* as being expression QTLs even though they did not pass WGS call rate filters in the GTEx dataset, as when we imputed the *TAOK1* STR into the GTEx dataset it was associated with *TAOK1* expression (**Methods**) and the *RHOT1* STR was associated with *RHOT1* expression in the Geuvadis dataset (**Methods**). The data summarized here is available in **Supplementary Tables 4**, **5**, **12** and **14**.



Figure 3: Concordance of White British STR effect directions in Black, South Asian and Chinese populations. The y-axis gives the fraction of STR associations measured in the discovery cohort that have the same direction of effect when measured in the replication population regardless of p-value. Brackets beneath the x-axis denote the binning of discovery -$\log_{10}$(p-values). Brown=genome-wide significant associations (discovery p<5e-8), orange=FINEMAP fine-mapped STR associations (discovery p<5e-8 and FINEMAP CP ≥ 0.8), teal=SuSiE fine-mapped STR associations (discovery p<5e-8 and SuSiE CP ≥ 0.8) and purple=confidently fine-mapped STR associations. Annotations above each bar indicate the number of STR-trait associations considered. We required confidently fine-mapped STR associations to have p-value < 1e-10, thus they do not appear in the left-most bin. The trends in these figures are somewhat sensitive to the choice of p-value bin boundaries so we additionally analyze this data using logistic models (**Supplementary Table 10**).

Fine-mapped STRs capture known associations

We identified multiple fine-mapped STRs that were previously demonstrated to have functional roles, providing supporting evidence for the validity of our pipeline. For instance, our confidently fine-mapped set implicates a protein-coding CTG repeat (**Supplementary Table 11**) to be the causal variant for one of the strongest signals for apolipoprotein B (p=1e-279; in one of the four peaks for this trait with minimal p-value exceeding our numeric precision) which forms the backbone of LDL cholesterol lipoproteins[38]. This locus is also one of the strongest signals for LDL cholesterol levels (two-sided association t-test p-value = 6e-236; fifth most-significant genome-wide peak) and the STR was marked as causal in 8 of 9 fine-mapping conditions. This repeat is bi-allelic in the UKB cohort with an alternate allele corresponding to deletion of three residues (Leu-Ala-Leu) in the signal peptide coded in the first exon of the apolipoprotein B (*APOB*) gene[39]. This deletion occurs in an imperfect region of the CTG repeat, with sequence CTGGCGCTG. In agreement with a previous study[40], we found that the short allele is associated with higher levels of both analytes. We discuss this locus further in **Supplementary Note 4**.

342 As another example, our initial fine-mapping implicates a multi-allelic AC repeat (**Supplementary**
343 **Table 11**) 6bp downstream of exon 4 of *SLC2A2* (also known as *GLUT2*, a gene that is most
344 highly expressed in liver) as causally impacting bilirubin levels (p=9e-18). However, this repeat
345 was not included in the final confidently fine-mapped set due to its FINEMAP CP of 0.61 not
346 passing our 0.8 threshold, despite its SuSiE CP of 0.99. The potential link between GLUT2 and
347 bilirubin is described in **Supplementary Note 5.** Previous studies in HeLa and 293T cells showed
348 that inclusion of exon 4 of *SLC2A2* is repressed by the binding of mRNA processing factor hnRNP
349 L to this AC repeat[41,42], implicating this STR in *SLC2A2* splicing. Notably, these studies did not
350 investigate the impact of varying repeat copy number. We examined this STR in GTEx liver
351 samples and did not find a significant linear association between repeat count and the splicing of
352 exon 4, though we did find evidence for association with the splicing of exon 6 (**Supplementary**
353 **Fig. 19**).

354 ***A trinucleotide repeat in* CBL *regulates platelet traits***

355 Most of the confidently fine-mapped STR associations identified by our pipeline have, to our
356 knowledge, not been previously reported. For example, this set includes positive associations
357 between the length of a highly polymorphic CGG repeat in the promoter of the gene *CBL* and both
358 platelet count (p=4e-83) and platelet crit (p=6e-103; 11th most-significant platelet crit peak;
359 **Supplementary Table 11**; **Fig. 4a-b**; **Supplementary Fig. 20**). This finding fits with observations
360 at other loci, as CG-rich repeats in promoter and 5' UTR regions have been strongly implicated in
361 transcriptomic regulation[13], often via epigenomic regulation[43,44]. This repeat in *CBL* is also
362 confidently fine-mapped to an association with mean sphered cell volume (p=7e-16;
363 **Supplementary Fig. 21**), but that is comparatively weaker and we do not discuss it here. For
364 both the platelet crit and platelet count phenotypes, SuSiE and FINEMAP identify two genome-
365 wide significant signals in this region, one of which they both localize to this STR. After
366 conditioning on a lead variant from the other signal (rs2155380), this STR becomes the lead
367 variant in the region by a wide margin (**Fig. 4c-d**). Conditioning on both rs2155380 and this STR
368 accounts for all the signal in the region (**Fig. 4e**). This supports the fine-mappers' prediction that
369 there are two signals in this region, one of which is driven by this STR.

370 This STR contains a common imperfection (rs7108857, which changes the second CGG copy to
371 TGG). That variant is in weak linkage disequilibrium (LD) with the length of the STR (r^2 in imputed
372 genotypes ranging between 0.023 (White British) and 0.175 (Chinese)) (**Fig. 4a**) and in strong LD
373 with the lead variant of the other signal in this region (rs2155380, White British r^2=97.8%). While

374 rs7108857 is more strongly associated with the platelet traits than the STR's length (platelet count
375 p=9e-86, platelet crit p=4e-98) and is associated with CBL expression in the GTEx cohort
376 (minimum p=2.04e-18 in Esophagus Muscularis), given the fine-mappers' results that the STR
377 length association is an independent signal, it is unsurprising that the STR-length association
378 remains after stratifying on the presence of this imperfection (**Fig. 4f**). This suggests that
379 imperfections and repeat lengths are different characteristics of repeats that may have distinct
380 associations.

381 The imputation of this STR displays more modest levels of concordance with WGS data than less
382 polymorphic loci (r^2=0.582 between length dosages from imputation and summed lengths from
383 WGS; additional statistics reported in **Supplementary Table 5**). Yet reassuringly, hard-called
384 genotypes from WGS show similar trends with both platelet traits (**Fig. 2b**, **Supplementary Fig.**
385 **20a,c-d**). Further, population-specific allele length distributions at this STR observed in UKB are
386 highly concordant with those observed in the 1000 Genomes Project (**Fig. 4a**, **Supplementary**
387 **Fig. 22**).

388 *CBL* codes for a protein in the RING finger subfamily of E3 ubiquitin ligases – a class of proteins,
389 each with specific target molecule(s), that ubiquitinate their targets and thus prime them for
390 downstream degradation. CBL targets the thrombopoietin receptor MPL[45], thereby
391 downregulating thrombopoietin signaling[46]. As thrombopoietin is the primary positive regulator of
392 platelet production[47], this implicates *CBL* as a negative regulator of platelet production. As further
393 evidence of this link, controlled experiments in mice demonstrate that loss of *CBL* function in
394 megakaryocytes, the bone marrow platelet progenitor cells, results in increased platelet counts[48].
395 Further, we observed that increased CCG length was negatively associated with *CBL* expression
396 in three tissues in the GTEx cohort[37] (each with p-value < 0.05 after multiple hypothesis correction;
397 **Supplementary Table 12**; **Fig. 4g**). This association replicated (p=0.007) in European individuals
398 in the Geuvadis cohort[49] (**Fig. 4h**). This data fits with the STR association with platelet traits and
399 the connection between *CBL* and platelet production, leading to an overall hypothesis that longer
400 CCG repeat alleles contribute to increased platelet count by decreasing CBL expression (**Fig. 4i**).



Figure 4: A highly polymorphic CGG repeat in the promoter of *CBL* influences platelet traits. (a) Distribution of STR alleles across populations. The x-axis gives STR length (in number of full repeat unit lengths, using WGS data) and y-axis gives the population frequency. The hatched portion of each bar corresponds to the alleles of that length that include a "TGG" imperfection at the second repeat (rs7108857). The ultra-rare alleles with T imperfections at other locations we label as 'perfect' for the sake of these analyses. Colors denote different UKB populations. Extreme allele lengths 3-6, 21-33, 36 and 37 each have frequency less than 1% in all populations and have been omitted. **(b) STR length vs. platelet count.** STR length sums were calculated from WGS data on (potentially related) White British participants that passed quality control. Error bars correspond to 95% confidence intervals. Only allele length sums with a population frequency of 0.1% or greater are displayed. Rounded population-wide counts are displayed for each sum. **(c-e) Association of variants at the *CBL* locus with platelet crit.** Association plots in the White British population are shown before conditioning **(c)**, after conditioning on rs2155380 **(d)**, and after conditioning on both rs2155380 and STR length **(e)**. Light blue=SNPs and indels; orange=STRs. Red line=genome-wide significance threshold, black circles=the $(CGG)_n$ STR and rs2155380. **(f) STR length vs. platelet count conditioned on the TGG imperfection rs7108857.** STR length sums were calculated from WGS data on (potentially related) White British individuals that passed quality control. Blue=individuals homozygous for no imperfection (n=86,974); orange=individual homozygous for the imperfection (n=11,778). For each category, only length sums with a frequency of 0.2% or greater in that category are displayed. **(g-h) STR length vs. *CBL* expression.** Associations are shown for Cultured Fibroblasts from GTEx (n=393) **(g)** and LCLs from Geuavdis (n=447) **(h).** Yellow=African, blue=European. For **(g-h)** only allele length sums with at least 5 corresponding participants are displayed. **(i) Proposed pathway for effect of STR length on platelet traits.** The arrow denotes a positive association, the capped lines denote negative associations. Interactions are captioned by their information sources.

424 ***Additional examples of confidently fine-mapped STR-trait associations***

425 We observe another 5' UTR CCG repeat in *BCL2L11* (also known as *BIM*) that is confidently fine-
426 mapped to eosinophil percentage (p=6e-75) and eosinophil count (p=5e-58) (**Supplementary**
427 **Table 11**). This repeat is the most strongly associated variant in the region for both traits, and
428 conditioning on it accounts for the entire signal in this region (**Supplementary Fig. 23**). Proteins
429 in the BCL-2 family are known to act as anti- or pro-apoptotic regulators. *BCL2L11* in particular is
430 pro-apoptotic and is required in the tightly regulated lifespan of myeloid lineage cells[50], which
431 include eosinophils. One mouse-model study showed that loss of repression of *BCL2L11* is
432 associated with lowered eosinophil counts[51] and another showed that *BCL2L11* knockout
433 increases counts of granulocytes, a class of cells including eosinophils[52]. This implicates
434 *BCL2L11* in the regulation of eosinophil count, supporting the connection we observe between
435 eosinophil count and the length of this STR.

436 While exonic repeats are potentially easier to interpret, a majority of our confidently fine-mapped
437 STRs fall in intronic regions. We resolve one of the strongest signals for mean platelet volume
438 (p<1e-300; one of twelve such peaks with p-values exceeding our numeric precision) to a multi-
439 allelic poly-A STR in an intron of the gene *TAOK1* (**Supplementary Table 11**; **Supplementary**
440 **Fig. 24a**). Conditioning on the length of this STR demonstrates that it explains the majority of the
441 signal in this region (**Supplementary Fig. 24b**). The same STR also shows a strong association
442 with platelet count, with p=2e-181 and a SuSiE CP of 1.

443 *TAOK1* is a protein kinase that plays a role in regulating microtubule dynamics[53] and microtubule
444 function is known to be critical to platelet generation[54]. The STR is in an intron of the canonical
445 *TAOK1* transcript but lies immediately downstream of a non-protein coding transcript of *TAOK1*
446 (ENST00000577583; which contains a retained intron) and is approximately 2.4kb upstream of a
447 differentially spliced exon. The STR also bears the hallmarks of a regulatory element: it is located
448 in a DNase hypersensitivity cluster and overlaps a transcription factor binding site for ESR1
449 (**Methods**). Although this STR was filtered from our initial GTEx callset due to low call rate (11%),
450 we used our haplotype panel to impute it into available SNP data for that cohort (**Methods**). While
451 we did not identify significant associations between repeat length and splicing of any nearby
452 exons, STR lengths showed modest but significant negative correlation with *TAOK1* expression
453 in 5 tissues (strongest p-value 8e-6 in thyroid; **Supplementary Fig. 24c-d**). The repeat also
454 showed associations with the expressions of nearby genes *ANKRD13B* (negative association;

455 strongest p-value 5e-05 in heart) and *TP53I13* (positive association; strongest p-value 6e-5 in
456 tibial nerve), although their potential role in platelet regulation is less clear.

457 In another confidently fine-mapped example we identify a previously unreported association
458 between a GTTT repeat in an intron of estrogen receptor beta (*ESR2*) and haemoglobin
459 concentration (p=1e-24), red blood cell count (p=3e-24) and haematocrit (p=1e-26), where
460 additional repeat copies correspond to lower measurements of all three traits (**Supplementary**
461 **Table 11**; **Supplementary Note 5; Supplementary Fig. 25**). Despite the relatively weak
462 discovery p-value and differing allele distributions between the White British and Black
463 populations (**Supplementary Fig. 25c**), all three associations replicate in the Black population
464 with p-values < 0.05. Consistent with these associations, *ESR2* ligand 17β-estradiol has been
465 implicated in the regulation of red blood cell production[55,56]. We found a significant negative
466 association between STR length and *ESR2* expression in two tissues in GTEx (each with p-value
467 < 0.05 after multiple hypothesis correction; **Supplementary Table 12**). While evidence suggests
468 a link between *ESR2* and red blood cell production, the expected direction of effect is unclear
469 given the highly tissue-specific isoform usage and functions of this gene (**Supplementary Note**
470 **5**). Nevertheless, our results support a role of this STR in red blood cell production through
471 regulation of *ESR2*.

472 We observed many additional associations of interest amongst the confidently fine-mapped
473 STRs. For example, we find multiple AC repeats in our set that are significantly associated with
474 expression of nearby genes. This includes a polymorphic AC repeat located in the 3' UTR of
475 *NCK2* which is associated with mean platelet volume (p=7e-29; **Supplementary Table 11;**
476 **Supplementary Fig. 26**). This repeat overlaps a binding site for the transcription factor PABPC1
477 and has a significant negative association with *NCK2* expression in multiple GTEx tissues
478 (strongest p=5e-7; **Supplementary Table 12**). We also find a highly polymorphic CCG repeat in
479 the 5' UTR of *RHOT1* that is associated with red blood cell distribution width (p=7e-13;
480 **Supplementary Table 11**). WGS data shows our imputation of this locus is poor, which is
481 unsurprising given the highly polymorphic nature of this STR. Nonetheless, the effect of this STR
482 is biologically plausible – this repeat overlaps a CTCF binding site, is located within a nucleosome
483 depleted region of a H3K27ac peak in LCLs, and shows a strong association with the expression
484 of *RHOT1* in LCLs from the Geuvadis dataset (p=2e-44 in Europeans, p=0.035 in Africans;
485 **Supplementary Fig. 27**). Finally, many STRs in our fine-mapped set consist of poly-A repeats.
486 While traditionally these have been particularly challenging to genotype[57], many such STRs,
487 including poly-A repeats in *MYO9B*, *DENND4A*, and *NRG4*, show strong statistical evidence of

488 causality and replicate across multiple population groups (**Fig. 2**). Taken together, these loci
489 exemplify the large number of confidently fine-mapped STRs our analysis provides for future
490 study.

491 Discussion

492 In this study, we imputed 445,720 STRs into the genomes of 408,153 participants in the UK
493 Biobank and associated their lengths with 44 blood cell and other biomarker traits. Using fine-
494 mapping, we estimate that STRs account for 5.2-7.6% of causal variants for these traits that can
495 be identified by GWAS. We stringently filtered the fine-mapping output to produce 119 confidently
496 fine-mapped STR-trait associations with strong evidence for causality across 93 distinct STRs
497 including some of the strongest signals for apolipoprotein B, platelet crit and mean platelet
498 volume. These confidently fine-mapped STRs replicated in the Black, South Asian and Chinese
499 UKB populations at higher rates than non-fine-mapped STRs ($p<0.02$ in each). A subset of these
500 STRs were associated with expression of nearby genes, providing evidence for their impact on
501 regulatory processes and explanations for their effects on the studied traits.

502 Broadly, our study highlights the importance of considering a more complete set of genetic
503 variants in complex trait analysis. It has been proposed that STRs may represent an important
504 source of the "missing heritability" associated with SNP-based GWAS[58,59]. Indeed, STRs, as well
505 as other complex variant types such as VNTRs[2], copy number variants[4], HLA types[60], and some
506 structural variants[61] are often highly multi-allelic and only imperfectly tagged by individual common
507 SNPs. This suggests that omitting these variants from analysis pipelines may overlook important
508 sources of causal variants and heritability. Further, we expect incorporation of this additional
509 source of causal variants, which we observe often exhibit population-specific allele distributions,
510 will improve downstream applications such as polygenic risk scores, particularly in constructing
511 scores that are more applicable across diverse populations.

512 While our results uncover many novel candidate causal STR variants, these findings are not
513 exhaustive. Our fine-mapping procedure was exceptionally conservative and excluded hundreds
514 of STR-trait associations strongly predicted to be causal in some but not all settings tested.
515 Further, whereas here we performed association tests with a fixed effects model, analysis with a
516 linear mixed model would increase power to detect additional associations. Additionally, compute
517 constraints limited our analysis to a small number of traits. In follow up studies we plan to extend
518 this analysis to a wide variety of medically-actionable traits.

519 Another limitation of our study is that it is based on imputed genotypes. Our SNP-STR reference
520 panel only included 27.5% of the 1.6 million STRs in the original HipSTR reference panel (**URLs**),
521 due to the exclusion of the many STRs with low heterozygosity, but also due to the exclusion of
522 non-autosomal STRs, most long repeats such as those implicated in pathogenic expansion
523 disorders, and many STR alleles that are common only in non-European populations[30]. Further,
524 imputed genotypes are inherently subject to some amount of noise, especially in non-European
525 populations. Despite these limitations, analysis of WGS data released for 200,025 UKB
526 participants[62] during the course of this study validated associations seen in imputed data.
527 Subsequently, popSTR calls at 2.5 million STRs were released for 150,000 of the participants
528 with WGS data[62]. Future studies which perform STR-based GWAS solely using WGS datasets
529 such as this should ameliorate the limitations mentioned above, enabling many future discoveries.

530 Methodological advances are also needed to support the study of STRs. Here we developed
531 associaTR, an open-source reproducible pipeline that enables future studies to conduct STR
532 length-based association tests. However, we envision that integrating support for STR length-
533 based tests and other complex variant associations into widely used GWAS toolkits would enable
534 more routine analysis of the full spectrum of human genetic variation. Improvements to our
535 association testing models are also likely to reveal new insights. In this study we only modeled
536 linear associations between STR lengths and trait values. Visualization of some of the
537 associations we identify suggests that these linear models only partially approximate those
538 signals. Many STR effects may be best described by non-linear models, such as quadratic or
539 sigmoid relationships between repeat copy numbers and traits. Yet fitting non-linear models would
540 require modeling the effects of the two alleles at each locus separately while simultaneously
541 controlling for the possibility of over-fitting, and is a topic of ongoing work. We also only tested
542 traits for association with the number of repeat units. However, inspection of individual loci reveals
543 that complex repeat structures are common (**Table 1**). Systematic evaluation of the potential for
544 epistasis between repeat imperfections and STR lengths, as well as between the lengths of
545 neighboring repeats, would potentially enable better understanding of the phenotypic impact of
546 STRs.

547 Importantly, our results highlight current challenges in performing statistical fine-mapping. We
548 found that fine-mapping results were in some cases highly sensitive to the choice of fine-mapping
549 tool, and to a lesser extent to data-processing choices and fine-mapper instabilities, where one
550 fine-mapping run would identify a variant as highly likely to be causal but a second would identify
551 it as having no causal impact. Further, our simulations suggest that fine-mappers have low

552 sensitivity rates even when sample sizes are large and all model assumptions are met. This
553 suggests statistical fine-mapping results should be interpreted with caution and evaluated for
554 sensitivity to model choices, and that further work is needed to make the process of fine-mapping
555 more robust.

556 Although fine-mapping inconsistencies were identified for SNPs and indels as well as STRs, they
557 were most prevalent for STRs. While this may in part be due to issues with imputing STR
558 genotypes, more research is needed to further evaluate the performance of current fine-mapping
559 tools on regions containing STRs. Additionally, there is a need for fine-mapping tools that can
560 model effects of multi-allelic variants. Existing fine-mapping frameworks in theory can accurately
561 model linear repeat-length associations, but we hypothesize that more detailed modeling of LD
562 between SNPs and individual STR alleles may enable more accurate model fitting procedures.
563 Similarly, during model fitting, existing tools often compare models which trade one causal variant
564 for another variant in close LD, but greater accuracy may be obtained by comparing models which
565 trade off a single, potentially causal, multi-allelic variant for multiple simultaneously-causal bi-
566 allelic variants.

567 Overall, our study provides a statistical framework for incorporating hundreds of thousands of
568 tandem repeat variants into GWAS studies, either via imputation, or using STR genotypes called
569 from WGS such as the newly released[62] UKB callset. Our study identifies dozens of novel
570 candidate variants for future mechanistic studies and demonstrates that STRs likely make a
571 widespread contribution to complex traits.

572 # Methods

573 ***Selection of UK Biobank participants***

574 We downloaded the fam file and sample file for version 2 of the phased SNP array data (referred
575 to in the UKB documentation as the 'haplotype' dataset) using the ukbgene utility (ver Jan 28
576 2019 14:09:15 - using Glibc2.28(stable)) described in UKB Data Showcase Resource ID 664
577 (**URLs**). The IDs from the sample file already excluded 968 individuals previously identified as
578 having excessive principal component-adjusted SNP array heterozygosity or excessive SNP
579 array missingness after call-level filtering[31] indicating potential DNA contamination. We further
580 removed withdrawn participants, indicated by non-positive IDs in the sample file as well as by IDs
581 in email communications from the UKB access management team. After the additional filtering,
582 data for 487,279 individuals remained.

583 We downloaded the sample quality control (QC) file (described in the sample QC section of UKB
584 Data Showcase Resource ID 531 (**URLs**)) from the European Genome-Phenome Archive
585 (accession EGAF00001844707) using pyEGA3[63]. We subsetted the non-withdrawn individuals
586 above to the 408,870 (83.91%) participants identified as White-British by column
587 `in.white.British.ancestry.subset` of the sample QC file. This field was computed by the
588 UKB team to only include individuals whose self-reported ethnic background was White British
589 and whose genetic principal components were not outliers compared to the other individuals in
590 that group[31]. In concordance with previous analyses of this cohort[31] we additionally removed data
591 for:

592 - 2 individuals with an excessive number of inferred relatives, removed due to plausible
593 SNP array contamination (participants listed in sample QC file column
594 `excluded.from.kinship.inference` that had not already been removed by the UKB
595 team prior to phasing)

596 - 308 individuals whose self-reported sex did not match the genetically inferred sex,
597 removed due to concern for sample mislabeling (participants where sample QC file
598 columns `Submitted.Gender` and `Inferred.Gender` did not match)

599 - 407 additional individuals with putative sex chromosome aneuploidies removed as their
600 genetic signals might differ significantly from the rest of the population (listed in sample
601 QC file column `putative.sex.chromosome.aneuploidy`)

602 Following these additional filters the data for 408,153 individuals remained (99.82% of the White
603 British individuals considered above).

604 ***SNP and indel dataset preprocessing***

605 We obtained both phased hard-called and imputed SNP and short indel genotypes made
606 available by the UKB. These variants were provided in reference genome hg19 coordinates, and
607 all analyses in this study, unless otherwise specified, were performed with hg19 coordinates.

608 *Phased hard-called genotypes:* We downloaded the bgen files containing the hard-called SNP
609 and indel haplotypes (release version 2) and the corresponding sample and fam files using the
610 ukbgene utility (UKB Data Showcase Resource 664 (**URLs**)). These variants had been genotyped
611 using microarrays and phased using SHAPEIT3[64] with the 1000 genomes phase 3 reference

612 panel[23]. Variants genotyped on the microarray were excluded from phasing and downstream
613 analyses if they failed QC on more than one microarray genotyping batch, had overall call-
614 missingness rate greater than 5% or had minor allele frequency less than 0.01%. Of the resulting
615 658,720 variants, 99.5% were single nucleotide variants, 0.2% were short indels (average length
616 1.9bp, maximal length 26bp), and 0.2% were short deletions (average length 1.9bp, maximal
617 length 29bp).

618 *Imputed genotypes:* We similarly downloaded imputed SNP data using the ukbgene utility
619 (release version 3). Variants had been imputed with IMPUTE4[31] using the Haplotype Reference
620 Consortium panel[22], with additional variants from the UK10K[24] and 1000 Genomes phase 3[23]
621 reference panels. The resulting imputed variants contain 93,095,623 variants, consisting of 96.0%
622 single nucleotide variants, 1.3% short insertions (average length 2.5bp, maximum length 661bp),
623 2.6% short deletions (average length 3.1bp, maximum length 129bp). This set does not include
624 the 11 classic human leukocyte antigen alleles imputed separately.

625 We used bgen-reader[65] 4.0.8 to access the downloaded bgen files in python. We used plink2[33]
626 v2.00a3LM (build AVX2 Intel 28 Oct 2020) to convert bgen files from both hard-called and imputed
627 SNPs to the plink2 format for downstream analyses. For hard-called genotypes, we used plink to
628 set the first allele to match the hg19 reference genome. Imputed genotypes already matched the
629 reference. Unless otherwise noted, our pipeline worked with imputed genotypes as non-reference
630 allele dosages, i.e. $\Pr(\text{heterozygous}) + 2 * \Pr(\text{homozygous alternate})$ for each individual.

631 ***STR imputation***

632 We previously published a reference panel containing phased haplotypes of SNP variants
633 alongside 445,720 autosomal STR variants in 2,504 individuals from the 1000 Genomes
634 Project[23,30] (**URLs**). This panel focuses on STRs ascertained to be highly polymorphic and well-
635 imputed in European individuals. Notably, this excludes many STRs known to be implicated in
636 repeat expansion diseases, STRs that are primarily polymorphic only in non-European
637 populations, or STRs that are too mutable to be in strong linkage disequilibrium (LD) with nearby
638 SNPs.

639 The IDs listed in the 'str' column of Supplementary Table 2 at that URL describe which variants
640 in the reference panel are STRs and which are other types of variants. That produces a list of
641 445,715 unique variant IDs and 5 IDs which are each assigned to four separate variants in the
642 reference panel VCFs. For the IDs with multiple assignments, we selected the variant that

643 appeared first in the VCF and discarded the others, leaving 445,720 unique STR variants each
644 with unique IDs.

645 While our analyses with these STRs were performed using hg19 coordinates unless otherwise
646 stated, we also provide hg38 reference coordinates for these STRs in the supplementary tables.
647 We obtained those coordinates using liftover (**URLs**) which resulted in identical coordinates as in
648 HipSTR's[6] hg38 STR reference panel (**URLs**). All STRs successfully lifted over to hg38
649 coordinates.

650 To select shared variants for imputation, we note that 641,582 (97.4%) of SNP and indel variants
651 that were hard-called and phased in the UKB participants were present in our SNP-STR reference
652 panel. As a quality control step, we filtered variants that had highly discordant minor allele
653 frequencies between the 1000 Genomes European subpopulations (**URLs**) and White British
654 individuals from the UKB. We first took a maximal unrelated set of the White British individuals
655 (see **Phenotype Methods** below) and then visually inspected the alternate allele frequency of
656 the overlapping variants (**Supplementary Fig. 1**) and chose to remove the 110 variants with an
657 alternate allele frequency difference of more than 12%.

658 We used Beagle[32] v5.1 (build 25Nov19.28d) with the tool's provided human genetic maps (**URLs**)
659 and non-default flag `ap=true` to impute STRs into the remaining 641,472 SNPs and indels from
660 the SNP-STR panel into the hard-called SNP haplotypes. Though we performed the above
661 comparison between reference panel Europeans and UKB White British individuals, we
662 performed this STR imputation into all UKB participants using all the individuals in the reference
663 panel. We chose Beagle because it can handle multi-allelic loci. Due to computational constraints,
664 we ran Beagle per chromosome on batches of 1000 participants at a time with roughly 18GB of
665 memory. We merged the resulting VCFs across batches and extracted only the STR variants.
666 Lastly, we added back the `INFO` fields present in the SNP-STR reference panel that Beagle
667 removed during imputation.

668 Unless otherwise noted, our pipeline worked with these genotypes as length dosages for each
669 individual, defined as the sum of length of each of the two alleles, weighted by imputation
670 probability. Formally, $dosage = \sum_{a \in A} len(a) * [Pr(hap_1 == a) + Pr(hap_2 == a)]$, where A is the
671 set of all possible STR alleles at the locus, $len(a)$ is the length of allele a, and $Pr(hap_i == a)$ is
672 the probability that the allele on the ith haplotype is a, output by Beagle in the `AP1` and `AP2`
673 `FORMAT` fields of the VCF file.

674 Estimated allele frequencies (**Fig. 1b**) were computed as follows: for each allele length L for each
675 STR, we summed the imputed probability of the STR on that chromosome to have length L over
676 both chromosomes of all unrelated participants. That sum is divided by the total number of
677 chromosomes considered to obtain the estimated frequency of each allele.

678 ***Inferring repeat units***

679 Each STR in the SNP-STR reference panel was previously annotated with a repeat period - the
680 length of its repeat unit - but not the repeat unit itself. We inferred the repeat unit of each STR in
681 the panel as follows: we considered the STR's reference allele and given period. We then took
682 each k-mer in the reference allele where k is the repeat period, standardized those k-mers, and
683 took their counts. We define the standardization of a k-mer to be the sequence produced by
684 looking at all cyclic rotations of that k-mer and choosing the first one lexicographically. For
685 example, the standardization of the k-mer CAG would be AGC. If the most common standardized
686 k-mer was less than twice as frequent as the second most common standardized k-mer, we did
687 not call a repeat unit for that STR (11,962 STRs; 2.68%). Otherwise, the most common
688 standardized k-mer was labeled as the forward-strand (based on the reference genome) repeat
689 unit for that STR. To infer the strand-independent repeat unit for the STR we looked at all rotations
690 of the forward-strand repeat unit in both the forward and reverse-complement directions and
691 chose whichever comes first lexicographically. For example the repeat unit for the STR
692 TGTGTGTG would be AC, while the forward-strand repeat unit would be GT. In the large majority
693 of cases the repeat unit identified by this approach is the unit which is duplicated or deleted in
694 alternate alleles, but this method of identifying repeat units does not consider alternate alleles and
695 so does not make that guarantee.

696 ***Phenotypes and covariates***

697 IDs listed in this section refer to the UKB Data Showcase (**URLs**).

698 We analyzed a total of 44 blood traits measured in the UKB. 19 phenotypes were chosen from
699 Category Blood Count (Data Field ID 100081) and 25 from Category Blood Biochemistry (Data
700 Field ID 17518). We refer to them as blood cell count and biomarker phenotypes respectively.
701 The blood cell counts were measured in fresh whole blood while all the biomarkers were
702 measured in serum except for glycated haemoglobin which was measured in packed red blood
703 cells (details in Resource ID 5636). The phenotypes we analyzed are listed in **Supplementary**

704 **Table 1**, along with the categorical covariates specific to each phenotype that were included
705 during association testing.

706 We analyzed all the blood cell count phenotypes available except for the nucleated red blood cell,
707 basophil, monocyte, and reticulocyte phenotypes. Nucleated red blood cell percentage was
708 omitted from our study as any value between the bounds of 0% and 2% was recorded as exactly
709 either 0% or 2% making the data inappropriate for study as a continuous trait. Nucleated red blood
710 cell count was omitted similarly. Basophil and monocyte phenotypes were omitted as those cells
711 deteriorate significantly during the up-to-24-hours between blood draw and measurement. This
712 timing likely differed consistently for different clinics, and different clinics drew from distinct within-
713 White British ancestry groups, which could lead to confounding with true genetic effects. See
714 Resource ID 1453 for more information. Reticulocytes were excluded from our initial pipeline. This
715 left us with 19 blood cell count phenotypes. For each blood cell count phenotype we included the
716 machine ID (1 of 4 possible IDs) as a categorical covariate during the association tests to account
717 for batch effects.

718 Biomarker measurements were subject to censoring of values below and above the measuring
719 machine's reportable range (Resource IDs 1227, 2405). **Supplementary Table 1** includes the
720 range limits and the number of data points censored in each direction. Five biomarkers (direct
721 bilirubin, lipoprotein(a), oestradiol, rheumatoid factor, testosterone) were omitted from our study
722 for having >40,000 censored measurements across the population (approximately 10% of all
723 data), since those would require analysis with models that take censoring into account. The
724 remaining biomarkers had less than 2,000 censored measurements. We excluded censored
725 measurements for those biomarkers from downstream analyses as they consisted of a small
726 number of data points. For each serum biomarker we included aliquot number (0-3) as a
727 categorical covariate during association testing as an additional step to mediate the dilution issue
728 (described in Resource ID 5636). Glycated haemoglobin was not subject to the dilution issue,
729 being measured in packed red blood cells and not serum, so no aliquot covariate was published
730 in the UKB showcase or included in our analysis.

731 For each phenotype we took the subset of the 408,153 individuals above that had a measurement
732 for that phenotype during the initial assessment visit or the first repeat assessment visit,
733 preferentially choosing the measurement at the initial assessment when measurements were
734 taken at both visits. We include a binary categorical covariate in association testing to distinguish
735 between phenotypes measured at the initial assessment and those measured at the repeat

736 assessment. Each participant's age at their measurement's assessment was retrieved from Data
737 Field ID 21003.

738 The initial and repeat assessment visits were the only times the biomarkers were measured. The
739 blood cell count phenotypes were additionally measured for those participants who attended the
740 first imaging visit. We did not use those measurements and for each phenotype excluded the
741 <200 participants whose only measurement for that phenotype was taken during the first imaging
742 visit as we could not properly account for the batch effect of a group that small (**Supplementary**
743 **Table 1**).

744 No covariate values were missing. Before each association test we checked that each category
745 of each categorical covariate was obtained by at least 0.1% of the tested participants. We
746 excluded the participants with covariate values not matching this criterion, as those quantities
747 would be too small to properly account for batch effects. In practice, this meant that for each
748 biomarker phenotype we excluded the <100 participants that were measured using aliquot 4, and
749 that for 8 of the biomarker phenotypes we additionally excluded the ≤125 participants that were
750 measured using aliquot 3 (**Supplementary Table 1**).

751 For each phenotype we then selected a maximally-sized genetically unrelated subset of the
752 remaining individuals using PRIMUS[66] v1.9.0. When multiple such maximal subsets existed (for
753 instance, wherever a single individual needed to be chosen from a family of two), one subset was
754 chosen arbitrarily, thus introducing some lack of reproducibility. Precomputed measures of
755 genetic relatedness between participants (described in UKB paper supplement section 3.7.1[31])
756 were downloaded using ukbgene (Resource ID 664). We ran PRIMUS with non-default options –
757 `-no_PR -t 0.04419417382` where the `t` cutoff is equal to 0.5^9, chosen so that two individuals
758 are considered to be related if they are relatives of third degree or closer. This left between
759 304,658 and 335,585 unrelated participants per phenotype (**Supplementary Table 1**).

760 Sex and ancestry principal components (PCs) were included as covariates for all phenotypes.
761 Participant sex was extracted from fam file available with hard called genotypes (see above). The
762 top 40 ancestry PCs were extracted from the corresponding columns of the sample QC file (see
763 the Participants **Methods** section above).

764 We then rank-inverse-normalized phenotype values for association testing. The remaining
765 unrelated individuals for each phenotype were ranked by phenotype value from least to greatest
766 (ties broken arbitrarily) and the phenotype value for association testing for each individual was

767 taken to be $normal\ quantile\left(\frac{sample\ rank\ +0.5}{n\ samples}\right)$. We use rank-inverse normalization as it is standard
768 practice, though it does not have a strong theoretical foundation[67] and only moderate empirical
769 support[68–71].

770 For each phenotype and its remaining unrelated individuals we standardized all covariates to
771 have mean zero and variance one for numeric stability.

772 ***Association testing***

773 We performed STR and SNP association testing separately. We developed associaTR to
774 streamline performing association tests between STR length and quantitative traits. While our
775 approach relies on a standard linear model, linear mixed models based on STR length dosages
776 would likely result in increased power and will be considered in future studies. As our downstream
777 analyses required STR and SNP associations to be comparable, we also used a standard linear
778 model for SNP association testing.

779 For STR association testing, the imputed VCFs produced by Beagle were accessed in python
780 with cyvcf2[72] 0.30.14 and v4.2.1 of our TRTools library[73]. In line with plink's recommendation for
781 SNP GWAS (**URLs**), 6 loci with non-major allele dosage < 20 were filtered. For each STR, we fit
782 the linear model $\vec{y} = \vec{g} * \beta_g + C * \overrightarrow{\beta_C} + \vec{\epsilon}$ where $\vec{y}$ is the vector of rank-inverse-normalized
783 phenotype values per individual, $\vec{g}$ is the vector of STR length dosage genotypes per individual,
784 β_g is the effect size of this STR, C is the matrix of standardized covariates, $\overrightarrow{\beta_C}$ is the vector of
785 covariate effect sizes, and $\vec{\epsilon}$ is the vector of errors between the model predictions and the
786 outcomes. Models were fit using the `regression.linear_model.OLS` function of the Python
787 statsmodels library v0.13.2 (**URLs**). Per GWAS best-practices, we used imputation dosage
788 genotypes instead of best-guess genotypes[74].

789 We used plink2[33] v2.00a3LM (build AVX2 Intel 28 Oct 2020) for association testing of imputed
790 SNPs and indels. For each analysis, plink first converts the input datasets to its pgen file format.
791 To avoid performing this operation for every invocation of plink, we first used plink to convert the
792 SNP and indel bgen files to pgen files a single time. We invoked plink once per chromosome per
793 phenotype. We used the plink flag `--mac 20` to filter loci with minor allele dosage less than 20
794 (**URLs**). Plink calculates minor allele counts across all individuals before subsetting to individuals
795 with a supplied phenotype, so this uniformly filtered 22,396,837 (24.1%) of the input loci from
796 each phenotype's association test leaving 70,698,786 SNPs and indels. Plink fit the same linear

797 model described above in the STR associations, except that $\vec{g}$ is the vector of dosages of the
798 non-reference SNP or indel allele.

799 For conditional regressions, we fit the model $\vec{y} = \vec{g} * \beta_g + \vec{f} * \beta_f + C * \overrightarrow{\beta_C} + \vec{\epsilon}$ where all the terms
800 are as described above, except $\vec{f}$ is the vector of per-individual genotypes of the variant being
801 conditioned on, and β_f is its effect size.

802 ***Comparison with Pan-UKB pipeline***

803 We compared the results of our pipeline to results available on the Pan UKBB[34] website (see
804 **URLs**) using bilirubin as an example trait. We matched variants between datasets on
805 chromosome, position, reference and alternate alleles, excluding variants not present in both
806 pipelines. We found our pipeline produced largely similar but somewhat less significant p-values
807 than those reported for European participants in Pan UKBB (**Supplementary Fig. 2**).

808 ***Defining significant peaks***

809 Given a peak width w (bp), we selected variants to center peaks on in the following manner:

810 1. Order all variants (of all types) from most to least significant. For variants which exceed
811 our pipeline's precision (p<1e-300), order them by their chromosome and base pair from
812 first to last. (These variants will appear at the beginning of the list of all variants).

813 2. For each variant: If the variant has p-value ≥ 5e-8, break. If there is a variant in either
814 direction less than w bp away which has a lower p-value, continue. Otherwise, add this
815 variant to the list of peak centers.

816 We define peaks to be the w (base pair) width regions centered on each selected variant. The
817 statistics given in the **Results** are calculated using $w = 250kb$. The identification of peaks in **Fig.**
818 **1c-d** was made with $w = 20mb$ for visualization purposes. Note that peaks within w bp of the end
819 of a chromosome will necessarily be smaller than w bp in width.

820 ***Identifying indels which are STR alleles***

821 Some STR variant alleles are represented both as alleles in our SNP-STR reference panel and
822 as indel variants in the UKB imputed variants panel. We excluded the indel representations of

823 those alleles from fine-mapping, as they represent identical variants and could confound the fine-
824 mapping process. For each STR we constructed the following interval:

825
$$\begin{cases} (start - 3, end + 3), & period = 1 \\ (start - 2 * period, end + 2 * period), & period > 1 \end{cases}$$
826

827 where $period$ is the length of the repeat unit. and $start$ and end give the coordinates of the STR
828 in base pairs. We call an indel an STR-indel if it only represents either a deletion of base pairs
829 from the reference or an insertion of base pairs into the reference (not both), overlaps only a
830 single STR based on the interval above, and represents an insertion or deletion of full copies of
831 that STR's repeat unit. We conservatively did not mark any STR-indels for STRs whose repeat
832 units were not called (see above) or for which the insertion or deletion was not a whole number
833 of copies of any rotation of the repeat unit.

834 ***Fine-mapping***

835 For each phenotype, we selected contiguous regions to fine-map in the following manner:

836 1. Choose a variant (SNP or indel or STR) with p-value < 5e-8 not in the major
837 histocompatibility complex (MHC) region (chr6:25e6-33.5e6).

838 2. While there is a variant (SNP or indel or STR) with p-value < 5e-8 not in the MHC region
839 and within 250kb of a previously chosen variant, include that variant in the region and
840 repeat.

841 3. This fine-mapping region is (min variant bp – 125kb, max variant bp + 125kb).

842 4. Start again from step 1 to create another region, starting with any variant with p-value <
843 5e-8 not already in a fine-mapping region.

844 This is similar to the peak selection algorithm above but is designed to produce slightly wider
845 regions so that we could fine-map nearby peaks jointly. We excluded the MHC because it is known
846 to be difficult to effectively fine-map. Note that peaks within 125kb of the end of a chromosome
847 will necessarily be smaller than the minimum 125kb width in that direction.

848 This produced 14,494 trait-regions. Due to computational challenges during fine-mapping (see
849 below), we excluded three regions (urate 4:8165642-11717761, total bilirubin 12:19976272-

850 22524428 and alkaline phosphatase 1:19430673-24309348) from downstream analyses (see
851 below), leaving 14,491 trait-regions.

852 We used two fine-mapping methods to analyze each region:

853 *SuSiE*[35]: For each fine-mapping trait-region, for each STR and SNP and indel variant in that region
854 that was not filtered before association testing, was not an STR-indel variants (see above) and
855 had p-value ≤ 5e-4 (chosen to reduce computational burden), we loaded the dosages for that
856 variant from the set of participants used in association testing for that phenotype. For those
857 regions we also loaded the rank-inverse-normalized phenotype values and covariates
858 corresponding to that phenotype. We separately regressed the covariates out of the phenotype
859 values and out of each variant's dosages and streamed the residual values to HDF5 arrays using
860 h5py v3.6.0 (**URLs**). We used rhdf5 v2.38.0 (**URLs**) to load the h5 files into R. We used an R
861 script to run SuSiE v0.11.42 on that data with non-default values `min_abs_corr=0` and
862 `scaled_prior_variance=0.005`. `min_abs_corr=0` forced SuSiE to output all credible sets
863 it found so that we could determine the appropriate minimum absolute correlation filter threshold
864 in downstream analyses. We set `scaled_prior_variance` to 0.005 which we considered is a
865 more realistic guess of the per-variant percentage of signal explained than the default of 20%,
866 although we determined that this parameter had no effect on the results (**Supplementary Note**
867 **3**). The SuSiE results for some regions did not converge within the default number of iterations
868 (100) or produced the default maximum number of credible sets (10) and all those credible sets
869 seemed plausible (minimum pair-wise absolute correlation ≥ 0.2 or size ≤ 50). We reran those
870 regions with the additional parameters `L=30` (maximum number of credible sets) and
871 `max_iter=500`. No regions failed to converge in under 500 iterations. We re-analyzed several
872 loci that produced 30 plausible credible sets again with `L=50`. No regions produced 50 plausible
873 credible sets. SuSiE failed to finish for two regions (urate 4:8165642-11717761, total bilirubin
874 12:19976272-22524428) in under 48 hours; we excluded those regions from downstream
875 analyses. A prior version of our pipeline had applied a custom filter to some SuSiE fine-mapping
876 runs that caused SNPs with total minor allele dosage less than 20 across the entire population to
877 be excluded. For consistency, any regions run with that filter which produced STRs included in
878 our confidently fine-mapped set were rerun without that filter. Results from the rerun are reported
879 in **Supplementary Table 4**.

880 SuSiE calculates credible sets for independent signals and calculates an alpha value for each
881 variant for each signal – the probability that that variant is the causal variant in that signal. We

882 used each variant's highest alpha value from among credible sets with purity ≥ 0.8 as its casual
883 probability (CP) in our downstream analyses (or zero if it was in no such credible sets). See
884 **Supplementary Note 1**.

885 *FINEMAP*[36]: We selected the STR and SNP and indel variants in each fine-mapping region that
886 were not filtered before association testing and had p-value < 0.05 (chosen to reduce
887 computational burden). We excluded STR-indels (see above). We constructed a FINEMAP input
888 file for each region containing the effect size of each variant and the effect size's standard error.
889 All `MAF` values were set to `nan` and the `ref` and `alt` columns were set to `nan` for STRs as this
890 information is not required. We then took the unrelated participants for the phenotype, loaded
891 their dosage genotypes for those variants and saved them to an HDF5 array with h5py v3.6.0
892 (**URLs**). To construct the LD input file required by FINEMAP, we computed the Pearson
893 correlation between dosages of each pair of variants. We then ran FINEMAP v1.4 with non-default
894 options `--sss --n-causal-snps 20`. In regions which FINEMAP gave non-zero probability
895 to their being 20 causal variants, we reran FINEMAP with the option `-n-causal-snps 40` and
896 used the results from the rerun. FINEMAP did not suggest 40 causal variants in any region.
897 FINEMAP caused a core dump when running on the region alkaline phosphatase 1:19430673-
898 24309348 so we excluded that region from downstream analyses. (For convenience, for the
899 regions containing no STRs, we directly ran FINEMAP with `--n-causal-snps 40`, unless those
900 regions contained less than 40 variants in which case we ran FINEMAP with `--n-causal-snps`
901 <#variants>).

902 We used the FINEMAP's PIP output for each variant in each region as its CP in downstream
903 analyses.

904 ***Alternative fine-mapping conditions***

905 We reran SuSiE and FINEMAP using alternative settings on trait-regions that contained one or
906 more STRs with p-value < 1e-10 and CP ≥ 0.8 in both the original SuSiE and FINEMAP runs.
907 Each new run differed from the original run in exactly one condition. We restricted our set of high-
908 confidence fine-mapped STRs (**Supplementary Table 5**) to those that had p-value < 1e-10 and
909 CP ≥ 0.8 in the original runs and maintained CP ≥ 0.8 in a selected set of those alternate
910 conditions.

911 For SuSiE, we evaluated using best-guess genotypes vs. genotype dosages as input. For
912 FINEMAP, we tested varying the p-value threshold, choice of non-major allele frequency

913 threshold, effect size prior, number of causal variants per region, and stopping threshold.
914 Additionally, we reran FINEMAP with no changed settings to examine potential FINEMAP
915 instability.

916 See **Supplementary Note 3** for a more detailed discussion of these various settings and their
917 impact on fine-mapping results.

918 ***Fine-mapping simulations***

919 We simulated phenotypes under additive genetic models and fine-mapped those phenotypes
920 separately at individual regions. Our simulations used real genotypes from White British UKB
921 participants and focused on regions originally identified by our GWAS to maintain realistic LD
922 patterns observed at regions with true signals. We used regions associated with platelet count as
923 it was the phenotype with the maximal number of fine-mapping regions (n=548).

924 *Strategies for choosing causal variants and effect sizes:* We applied three different strategies for
925 choosing causal variants from these regions and choosing their effect sizes. For each strategy,
926 we simulated phenotypes from those variants, ran SuSiE and FINEMAP on all SNPs and STRs
927 in the region against the simulated phenotypes and determined whether the fine-mappers
928 correctly identified the variants simulated to be causal.

929 For the first strategy we chose causal SNPs and indels at random, weighting by minor allele
930 frequency (MAF). For this strategy, we did not simulate causal STRs. To begin, we took all
931 SNPs/indels in all platelet count regions that had either FINEMAP CP ≥ 0.5 or SuSiE CP ≥ 0.5
932 and binned them by MAF (bin boundaries = [0.01%, 0.1%, 10%, 50%]), excluding all variants with
933 MAF < 0.01%. We assigned each bin a relative weight by the proportion of causal variants in that
934 bin vs in all bins as compared to the proportion of all variants in that bin vs all bins, noting that
935 these weights were relatively consistent across bins (within a factor of 2, **Supplementary Table**
936 **6**). Using those bin weights, for each fine-mapping region, we then drew causal SNPs/indels at
937 random from all SNPs/indels in the region, with each variant's chance of being drawn weighted
938 by the bin that its MAF corresponds to. For each bin, we also collected all observed effect sizes
939 of all variants falling in that bin, noting that as expected the effect sizes for common variants were
940 smaller than those for rarer variants (**Supplementary Fig. 6**). For each variant chosen to be
941 causal, we drew an effect size from the corresponding MAF bin. This strategy is designed so that
942 the distributions of MAFs and effect sizes of causal variants in our simulations are similar to those

943 observed for fine-mapped variants for the real phenotype. We repeated this strategy nine times
944 for each simulation region, three times each choosing sets of one, two and three causal variants.

945 While the first strategy allows for a wide range of simulations by drawing causal variants at
946 random, it may not capture systematic differences between the LD patterns of causal variants
947 and the LD patterns of non-causal variants in causal regions. To address this, for the second
948 strategy we chose variants fine-mapped by SuSiE for platelet count for simulating as causal as
949 these may more closely capture LD patterns of truly causal variants. Specifically, we ran SuSiE
950 on all the SNPs and indels in the fine-mapping region with $p < 0.0005$ against real platelet count
951 data. Note that by only running SuSiE against the SNP and indel variants in the region, we forced
952 SuSiE to give us the most plausibly causal set of SNPs/indels in the region under the condition
953 that no STRs are causal. We discarded non-pure credible sets (those with variants in less than
954 0.8 r^2) as we expect them to be less reliable in identifying truly causal variants. In the 458/548
955 regions where there were any pure credible sets remaining, we took the top variant from each of
956 the remaining credible sets to use as causal for simulations, using their effect sizes measured
957 against the real platelet count trait as their effect sizes for simulation. For each region, we used
958 its causal variant set to simulate three phenotypes (which are distinct due to different noise terms).

959 While this second strategy may capture more realistic causal LD patterns compared to choosing
960 causal variants at random, it has the drawback that it relies on the accuracy of fine-mapping to
961 choose the causal variants, which is what we are trying to assess. Strategy one relies on fine-
962 mappers as well, but to a much lesser extent, using them only to identify causal variant MAF and
963 effect size distributions. A second caveat to strategy two is that by restricting to pure credible sets,
964 we likely omit real signals which SuSiE could not resolve well.

965 For our third strategy, we paralleled our second strategy, except instead of fine-mapping platelet
966 count against only SNPs and indels, we fine-mapped it against all the variants in the region
967 (including STRs), thus allowing it to select STRs as causal for simulation. We continued with
968 simulations as in the second strategy for the 52/548 regions where SuSiE identified a causal STR.
969 This third strategy is the only strategy we performed which simulated causal STRs. As the number
970 of simulations performed with this third strategy was limited, we only use it to contribute briefly to
971 our discussion in the main text.

972 *Simulating phenotypes:* Let V represent the set of causal variants for a region. For each variant
973 $v \in V$ let $\overrightarrow{g_v}$ represent a vector of participant genotype dosages and β_v denote the variant's

chosen effect size. Assuming additive and independent contributions of each variant, we simulated a vector of phenotypes ($\vec{y}$) as $\vec{y} = \sum_{v \in V} \overrightarrow{g_v} * \beta_v + \vec{\epsilon}$, where $\vec{\epsilon} \sim \mathrm{N}(0, \mathrm{diag}(1 - \sum_{v \in V} \beta_v^2 Var[\overrightarrow{g_v}]))$ so that similarly to the real, normalized, phenotypes used for our GWAS, the resulting phenotypes have mean 0 and variance 1.

Evaluating fine-mapping on simulated phenotypes: For each simulated phenotype and region we performed association testing of the variants in that region using the same methods as in the main analysis, excepting that we included no covariates and that the phenotypes were not subjected to rank-inverse normalization. We then ran FINEMAP and SuSiE against the variants in the region as described above (in particular, FINEMAP runs were restricted to variants with p<0.05, SuSiE runs to variants with p<0.0005), with the difference that the fine-mapping region was not recalculated from the simulated phenotype GWAS statistics but instead exactly matched to the causal region determined from the platelet count GWAS. Once fine-mappers were run, we calculated STR contribution statistics as for fine-mapping runs on the UKB blood traits (**Supplementary Tables 7-8**).

Simulation caveats: Many choices in the design of these simulations affect the interpretation of their results. Notably, these simulated phenotypes make standard assumptions of additive genetic architectures, including no non-linear effects, no epistasis between variants, and that the environmental contribution to each phenotype is both independent of an individual's genotypes and normally distributed. These simulations also assume that there are no confounding covariates. Additionally, these simulations choose the effect sizes of causal variants from effect sizes calculated in our platelet count GWAS. As effect sizes calculated in the GWAS were measured in mono-variant regressions against platelet count, they will be mis-estimated according to the corresponding variant's LD to all causal variants in the region in which it resides.

Further, we note that not recalculating the fine-mapping regions may artificially inflate the rate at which strategy one identifies causal variants, as when causal variants in strategy one were randomly chosen to fall near the edges of the region, there would be fewer variants in LD with those variants and fine-mapping them would be easier. This may contribute to the observation in **Supplementary Table 7** that both fine-mappers select STRs in simulation strategy two much more than in simulation strategy one. We also speculate that STRs truly causal for platelet count would contribute to that observation: if those STRs are well tagged by SNPs, strategy two's run of SuSiE would likely select those tagging SNPs for causal simulation. Then fine-mapping of those

1005 simulated phenotypes would have a relatively high chance of confusing those SNPs with the
1006 STRs they tag.

1007 Lastly, we observe that FINEMAP mostly identifies variants with low p-values, while a p-value
1008 cutoff is necessary for accurate SuSiE results. Once a p-value cutoff is applied, we see that the
1009 fine-mappers' results are almost entirely consistent with one another, in large distinction from how
1010 they perform when applied to real datasets, suggesting that there are some features of the
1011 architectures of blood traits are not captured by these simulations.

1012 ***Validation of imputation results for fine-mapped STRs using WGS data***

1013 We worked with WGS CRAM files for 200,025 UKB participants on the UKB Research Analysis
1014 Platform cloud solution provided by DNA Nexus. This data was aligned to reference genome
1015 hg38. HipSTR was unable to load the index files for the CRAM files of 10 participants, possibly
1016 due to file corruption. Removing those participants left us with 200,015 participants. We
1017 inadvertently truncated the participant list, leaving 200,000 participants. From that participant list
1018 we called genotypes of the 409 STRs in **Supplementary Table 4** using HipSTR[6] in batches of
1019 500 participants, using the flag `--min-reads 10` and allowing HipSTR to estimate stutter-error
1020 models from the data. We merged batches using MergeSTR[73]. We performed call level filtering
1021 using DumpSTR[73] with the flags `--hipstr-min-call-Q 0.9 --hipstr-min-call-DP 10`
1022 `--hipstr-max-call-DP 10000 --hipstr-min-supp-reads 2 --hipstr-max-call-`
1023 `stutter 0.15 --hipstr-max-call-flank-indel 0.1`. After calling all 200,000
1024 individuals we summarized their genotypes separately per population, noting that 166,638
1025 individuals were in our set of QC'ed (potentially related) White British UKB participants,
1026 accounting for 40.8% of the QC'ed White British participants.

1027 We did not apply any locus-level filters, such as Hardy-Weinberg equilibrium, to our WGS results.
1028 We report per-locus WGS call rates for QCed (potentially related) individuals in each population.
1029 We used liftOver to lift the hg38 WGS calls to the hg19 reference genome (**URLs**). To compare
1030 the WGS calls to the imputed STR calls, we used CompareSTR from TRTools[73] branch
1031 `compareSTR_upgrade` using the flags `--ignore-phasing --balanced-accuracy --`
1032 `vcf2-beagle-probabilities` . We report multiple metrics at each locus, specifically
1033 concordance, the mean absolute summed-length difference, r^2 and dosage r^2.

1034 For the following definitions, let X be the set of all samples, A be the set of all possible STR length
1035 alleles at a locus, let $S = \{a_1 + a_2 | a_1, a_2 \in A\}$ be the set of all summed-lengths possible at a locus

(including the case of homozygous individuals when $a_1 = a_2$), for $x \in X$ let $s_{x,WGS}$ be the summed-length call for sample x from WGS data, and for $x \in X, s \in S$ let $Pr_{x,imp}(s)$ be the probability that sample x has a summed imputation length of s as output by the Beagle `AP1` and `AP2 FORMAT` fields in the imputed VCF file.

We report (summed-length) per-locus concordances as $E_{x \in X}[Pr_{x,imp}(s_{x,WGS})]$. This metric has the advantage of being intuitive but is biased upwards for loci with a single very common allele and so should be interpreted cautiously for such loci. We also report mean absolute summed length differences as $E_{x \in X}[\sum_{s \in S} Pr_{x,imp}(s) \cdot |s_{x,WGS} - s|]$. This metric has similar caveats as the concordance metric. However, for highly multi-allelic loci where concordance is low, this metric can help quantify how close (or not) imputed calls are to the actual genotypes. We calculated r^2 as the square of the weighted Pearson correlation between $s_{x,WGS}$ and s for each sample $x \in X$ and all possible summed-lengths $s \in S$ (so that there are $|X| \cdot |S|$ total values being correlated), weighting by the imputation probabilities $Pr_{x,imp}(s)$. This correlation measure is more comparable across loci with different numbers of alleles than concordance. It has the downside of being less intuitive and of being more sensitive to the WGS-vs-imputation concordance of rare long and short alleles than the WGS-vs-imputation concordance of common average-length alleles. We report dosage r^2 as the square of the Pearson correlation between $s_{x,WGS}$ and the dosage $\sum_{s \in S} s \cdot Pr_{x,imp}(s)$ for each sample $x \in X$. Dosage r^2 is strictly greater than or equal to the weighted r^2 measure. While the weighted r^2 measure more directly measures the concordance of individual imputation probabilities with the WGS calls, the dosage r^2 measure better estimates how analyses like GWAS, which condense imputed probabilities into dosages, will perform.

Lastly, at each locus we report the frequency of each summed-length according to WGS calls, and for all samples with each WGS summed-length we report the probability that imputation concurs with that length: $E_{X|s_{x,WGS}=s}[Pr_{x,imp}(s_{x,WGS})]$.

Replication in other populations

We separated the participants not in the White British group into population groups using the self-reported ethnicities summarized by UKB showcase data field 21000 (**URLs**). This field uses UKB showcase data coding 1001. We defined the following five populations based on those codings (counts give the maximal number of unrelated QC'ed participants, ignoring per-phenotype missingness):

1066 - Black (African and Caribbean, n=7,562, codings 4, 4001, 4002, 4003)

1067 - South Asian (Indian, Pakistani and Bangladeshi, n=7,397, codings 3001, 3002, 3003)

1068 - Chinese (n=1,525, coding 5)

1069 - Irish (n=11,978, coding 1002)

1070 - Other White (White non-Irish non-British, n=15,838, coding 1003)

1071 Self-reported ethnicities were collected from participants at three visits (initial assessment, repeat
1072 assessment, first imaging). The above groups also exclude participants who self-reported
1073 ethnicity at more than one visit and where their answers corresponded to more than one
1074 population (after ignoring 'prefer not to answer' `code=-3` responses). We did not include any
1075 participants who were neither in the White British population nor any of the above populations.
1076 Unlike for the determination of White British participants, genetic principal components were not
1077 used as filters for these categories.

1078 For the association tests in these populations we applied the same procedures for sample quality
1079 control, unrelatedness filtering, phenotype transformations, and preparing genotypes and
1080 covariates as in the White British group. The only changes in procedure were that (a) we removed
1081 categorical covariate values where there were fewer than 50 participants with that value, (in which
1082 case we also removed those participants from analysis, as that would be too few to properly
1083 control for batch effects), whereas for White British individuals we used a cutoff of 0.1% instead
1084 and (b) we also applied this cutoff to the visit of measurement categorical covariate, resulting in
1085 some association tests that excluded individuals whose first measurement of the phenotype
1086 occurred outside the initial assessment visit. See **Supplementary Table 9** for details.

1087 STRs were marked as replicating in another population (**Fig. 2**) if any of the traits confidently fine-
1088 mapped to that STR share the same direction of effect as the White British association and
1089 reached association p-value < 0.05 after multiple hypothesis correction (i.e. if there are three
1090 confidently fine-mapped traits, then an STR is marked as replicating in the Black population if any
1091 of them has association p-value < 0.05/3 = 0.0167 in the Black population).

1092 We validated imputation STR lengths using WGS data in these populations as was done in the
1093 White British population, and report these results in **Supplementary Tables 4** and **5**. The number
1094 of samples in our QC'ed set that had WGS data were 2,990 Black, 3,373 South Asian, 619

Chinese, 5,174 Irish and 6,428 Other White samples, all roughly 40% of their respective populations.

Logistic regression analysis of replication direction

We used logistic regression to quantitatively assess the impact of fine-mapping on replication rates while controlling for discovery p-value. For this analysis, to have sufficient sample sizes, we defined that an STR-trait association replicates in another population if it had the same direction of effect in that population as in the White British population, regardless of the replication p-value.

For each of the five replication populations, we compared four categories: all gwsig (genome-wide significant associations in the discovery population, i.e. p-value < 5e-8), FINEMAP (discovery p-value < 5e-8 and FINEMAP CP ≥ 0.8), SuSiE (discovery p-value < 5e-8 and SuSiE CP ≥ 0.8) and confidently fine-mapped STR (STR associations in our confidently fine-mapped set).

For each comparison, we used the function `statsmodels.formula.api.logit` from statsmodels v0.13.2 (**URLs**) to fit the logistic regression model:

$$\texttt{replication_status} \sim \texttt{STR_in_target_category} + \log_{10}(\texttt{p-val}) + \log_{10}(\texttt{p-val})^2$$

where `replication_status` is a binary variable indicating whether or not the given STR-trait association replicated in the other population, `p-val` is the discovery p-value, and `STR_in_target_category` is a binary variable indicating if the STR is in the target category.

For each replication population, we considered various models:

- All gwsig STRs with either FINEMAP, SuSiE, or confidently fine-mapped STRs as the target category.
- All FINEMAP STRs with confidently fine-mapped STRs as the target category.
- All SuSiE STRs with confidently fine-mapped STRs as the target category.

For each model, we performed a one-sided t-test for the hypothesis that the coefficient for the covariate `STR_in_target_category` was greater than zero, i.e. testing that being in the target category increased the predicted chance of replicating in the chosen population (**Supplementary Table 10**).

1123 ***Gene and transcription factor binding annotations***

1124 For all analyses not using GTEx data, gene annotations were based on GENCODE 38[75] (**URLs**).
1125 Transcription factor binding sites and DNaseI hypersensitivity regions were identified by
1126 ENCODE[76] overlapping several loci (*TAOK1*, *RHOT1* and *NCK2*) through visual inspection of the
1127 "Txn Factor ChIP" and "DNase Clusters" tracks in the UCSC Genome Browser[77] and using the
1128 "Load from ENCODE" feature of the Integrative Genomics Viewer[78].

1129 ***Enrichment testing***

1130 We tested the following categories for enrichment in STRs identified by our association testing
1131 pipeline:

1132 - Genomic feature: We grouped records by feature type and restricted to features with
1133 support level 1 or 2 except for genes which don't have a support level. We used bedtools[79]
1134 to compute which features intersect each STR and the distance between each STR and
1135 the nearest feature of each feature type.
1136 - Repeat unit: unit length and standardized repeat unit were defined as described above.
1137 Repeat units occurring in <1000 STRs were grouped by repeat length. Repeats whose
1138 unit could not be determined were considered as a separate category.
1139 - Overlap with expression STRs (eSTR): we tested for overlap with either all eSTRs or fine-
1140 mapped eSTRs as defined in our previous study to identify STR-gene expression
1141 associations in the Genotype Tissue Expression (GTEx) cohort[13].

1142 Enrichment p-values were computed using a Chi-squared test (without Yate's continuity
1143 correction) if all cells had counts ≥ 5. A two-sided Fisher's exact test was used otherwise. Chi-
1144 squared and Fisher's exact tests were implemented using the `chi2_contingency` and
1145 `fisher_exact` functions from the Python scipy.stats package v1.7.3 (**URLs**).

1146 ***Expression association analysis in GTEx***

1147 We had previously analyzed associations[13] between STRs and gene expression in GTEx V7.
1148 Here we reanalyzed those associations using GTEx V8. We obtained 30x Illumina whole genome
1149 sequencing (WGS) data from 652 unrelated participants in the Genotype-Tissue Expression
1150 project (GTEx)[37] through dbGaP accession number phs000424.v8.p2. WGS data was accessed
1151 using fusera (**URLs**) through Amazon Web Services. We genotyped STRs using HipSTR[6] v0.5

1152 with HipSTR's hg38 reference STR set (**URLs**). All individuals were genotyped jointly using
1153 default parameters. GTEx's whole genome sequencing procedure is not PCR-free, which likely
1154 contributed to low call rates at long poly-A and GC-rich STRs. The resulting VCFs were filtered
1155 using DumpSTR from TRTools[73], using the parameters `--filter-hrun --hipstr-min-`
1156 `call-Q 0.9 --hipstr-min-call-DP 10 --hipstr-max-call-DP 1000 --hipstr-`
1157 `max-call-flank-indel 0.15 --hipstr-max-call-stutter 0.15 --min-locus-`
1158 `callrate 0.8 --min-locus-hwep 0.00001` . We also removed STRs overlapping
1159 segmental duplication regions (UCSC Genome Browser[80] h38.genomicSuperDups table).
1160 Altogether, 728,090 STRs remained for downstream analysis.

1161 The *TAOK1* STR locus was filtered from this genotyping for having an 11% call rate, so we
1162 imputed the genotypes at that locus into the GTEx cohort. GTEx V7 SNP files were downloaded
1163 from GTEx data portal (**URLs**). SNPs on chromosome 17 were extracted and filtered to remove
1164 using vcftools with the parameters `--maf 0.01 --mac 3 --we 0.00001 --max-missing`
1165 `0.8 --minQ 30` . We used Beagle v5.2 (beagle.28Jun21.220.jar) with the tool's provided human
1166 genetic maps to impute STRs into the GTEx SNPs using the same reference panel used for
1167 imputation in the UKB cohort above[30]. From this imputation we took the best-guess genotypes of
1168 the *TAOK1* STR. We lifted the coordinates of the *TAOK1* STR from hg19 to hg38 using liftOver.

1169 For each tissue, we obtained gene-level and transcript-level transcripts-per-million (TPM) values,
1170 exon-exon junction read counts, and exon read counts for each participant from GTEx Analysis
1171 V8 publicly available from the GTEx project website (**URLs**). Gene annotations are based on
1172 GENCODE v26[75]. We focused on 41 tissues with expression data for at least 100 samples
1173 (**Supplementary Table 13**). We restricted our analysis to protein-coding genes, transcripts and
1174 exons that did not overlap segmental duplication regions.

1175 To control for population structure, we obtained publicly available genotype data on 2,504
1176 unrelated individuals from the 1000 Genomes project[23] genotyped with Omni 2.5 SNP genotyping
1177 arrays. We performed the following principal components analysis jointly on that data and the
1178 SNP genotypes based on WGS of the 652 individuals above. We removed all indels, multi-allelic
1179 SNPs, and SNPs with minor allele frequency less than 5%. We then used plink v.1.90b3.44 to
1180 subset these remaining SNPs to a set of SNPs in approximate linkage equilibrium with the
1181 command `--indep 50 5 2`. We excluded any remaining SNPs with missingness rate 5% or
1182 greater. We lastly ran principal component analysis using smartpca70[81] v.13050 with default
1183 parameters.

1184 We removed genes with TPM less than 1 in more than 90 percent of individuals. PEER factors[82]
1185 were calculated using PEER v1.0 from the TPM values which remained after filtering. For each
1186 gene, we tested for association with each STR within 100kb. For each test we performed a linear
1187 regression between the STR's dosage (sum of allele lengths) and gene expression (TPM). We
1188 included the loadings of the top five genotype principal components as computed above and the
1189 top N/10 PEER factors as covariates. The number of PEER factors was chosen to maximize the
1190 number of significant associations across a range of tissues. We did not include sex or age as
1191 covariates.

1192 For each STR we computed Bonferroni-adjusted p-values to control for the number of gene ×
1193 tissue tests performed for that STR. Associations that remained with adjusted $p < 0.05$ are shown
1194 in **Supplementary Table 12**.

1195 We additionally used the GTEx cohort to test for an association between length of the bilirubin-
1196 associated dinucleotide repeat identified in *SLC2A2* with splicing efficiency in liver. We obtained
1197 exon-exon junction read counts and exon read counts from the GTEx website (**URLs**). We
1198 calculated the percent spliced in value for each exon in the manner suggested by Schafer et al.[83].
1199 We performed a linear regression to test between the STR's dosage and the percent spliced in of
1200 each exon within 10kb, using the top 5 ancestry principal components as covariates.

1201 ***Methylation association analysis in GTEx***

1202 This analysis used the same STR data and genotype principal components as the GTEx
1203 expression association analysis above.

1204 We downloaded genome-wide DNA methylation (DNAm) profiling results from the NCBI GEO
1205 database under accession number GSE213478. This contained DNA methylation levels from the
1206 whole blood of 47 individuals who had been genotyped, including 754,054 autosomal CpG loci
1207 which passed quality control checks in that dataset (**URLs**)[84]. We lifted those loci from hg19 to
1208 hg38. We performed per-locus inverse-normalization of the DNAm data prior to downstream
1209 analysis. We calculated 5 PEER factors from the normalized DNAm data across quality-controlled
1210 loci from all chromosomes (including sex chromosomes) using PEER v1.0[82], choosing 5 factors
1211 to match the number of PEER factors used by the methylation study which generated this data[84].

1212 We tested for associations between the methylation of each autosomal CpG locus and the length
1213 of each STR located within 100kb of that locus. For each such pair, we performed a linear

1214 regression between the STR's dosage (sum of allele lengths across both chromosomes) and the
1215 inverse-normalized DNAm levels of that CpG locus, including the top five genotype principal
1216 components and the 5 PEER factors as covariates. We compared the effect sizes of these
1217 associations with those from another paper studying STR-methylation correlations in two separate
1218 cohorts in whole blood[17] and found that they were broadly consistent ($r=0.73$, $p<10^{-200}$,
1219 **Supplementary Fig. 18c**).

1220 For each STR we computed Bonferroni-adjusted p-values to control for the number of CpG tests
1221 performed for that STR. Associations that remained with adjusted $p < 0.05$ are shown in
1222 **Supplementary Table 14**.

1223 ***Expression analysis of the* CBL *and* RHOT1 *STRs in Geuvadis***

1224 We applied HipSTR[6] v0.6.2 to genotype STRs from HipSTR's hg38 reference STR set (**URLs**) in
1225 2,504 individuals from the 1000 Genomes Project[85] for which high-coverage WGS data was
1226 available. Gene-level reads per kilobase per million reads (RPKM) values based on RNA-seq in
1227 lymphoblastoid cell lines for 462 1000 Genomes participants were downloaded from the Geuvadis
1228 website (**URLs**). Of these, 449 individuals were genotyped by HipSTR.

1229 Similar to the GTEx analysis, we performed a linear regression between STR dosage (sum of
1230 allele lengths) and RPKM, adjusting for the top 5 genotype principal components (computed as
1231 above for the GTEx analysis, but only on populations included in Geuvadis and separately for
1232 Europeans and Africans) and N/10 (45) PEER factors as covariates. PEER analysis was applied
1233 using PEER v1.0 to the matrix of RPKM values after removing genes overlapping segmental
1234 duplications and those with RPKM less than 1 in more than 90% of LCL samples. We performed
1235 a separate regression analysis for African individuals (YRI) and European individuals (CEU, TSI,
1236 FIN, and GBR). After restricting to individuals with non-missing expression data and STR
1237 genotypes and who were not filtered as PCA outliers by smartpca[81,86] included in EIGENSOFT
1238 v6.1.4, 447 LCL samples remained for analysis in each case (num. EUR=358, and AFR=89 for
1239 *CBL*, EUR=359 and AFR=88 for *RHOT1*).

URLs

- 1000 Genomes individuals: https://www.internationalgenome.org/data-portal/sample using the "Download the list" tab
- associaTR: https://trtools.readthedocs.io/
- Beagle Human genetic maps: https://bochet.gcc.biostat.washington.edu/beagle/genetic_maps/
- fusera: https://github.com/ncbi/fusera
- GENCODE 38 (hg19): http://ftp.ebi.ac.uk/pub/databases/gencode/Gencode_human/release_38/GRCh37_mapping/gencode.v38lift37.annotation.gff3.gz
- Geuvadis: https://www.ebi.ac.uk/arrayexpress/experiments/E-GEUV-1/files/analysis_results/?ref=E-GEUV-1
- GTEx v8:
    - https://www.gtexportal.org/home/datasets
    - https://storage.googleapis.com/gtex_analysis_v8/rna_seq_data/GTEx_Analysis_2017-06-05_v8_RNASeQCv1.1.9_gene_tpm.gct.gz
    - https://storage.googleapis.com/gtex_analysis_v8/rna_seq_data/GTEx_Analysis_2017-06-05_v8_STARv2.5.3a_junctions.gct.gz
    - https://storage.googleapis.com/gtex_analysis_v8/rna_seq_data/GTEx_Analysis_2017-06-05_v8_RNASeQCv1.1.9_exon_reads.parquet
- h5py https://github.com/h5py/h5py
- HDF5: https://www.hdfgroup.org/HDF5/
- HipSTR STR reference https://github.com/HipSTR-Tool/HipSTR-references/raw/master/human/hg38.hipstr_reference.bed.gz
- liftOver:
    - https://genome.ucsc.edu/cgi-bin/hgLiftOver , accessed on 2023/03/09
    - https://hgdownload.soe.ucsc.edu/goldenPath/hg19/liftOver/hg19ToHg38.over.chain.gz
    - ftp://hgdownload.soe.ucsc.edu/goldenPath/hg38/liftOver/hg38ToHg19.over.chain.gz
- Methylation in GTEx:
    - Overview: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE213478
    - CpG locations: https://www.ncbi.nlm.nih.gov/geo/download/?acc=GSE213478&format=file

- NCBI protein database: https://www.ncbi.nlm.nih.gov/protein
- Pan-UKB:
    - Overview: https://pan.ukbb.broadinstitute.org/downloads
    - manifest: https://docs.google.com/spreadsheets/d/1AeeADtT0U1AukliiNyiVzVRdLYPkTbruQSk38DeutU8
    - bilirubin SNP summary statistics: https://pan-ukb-us-east-1.s3.amazonaws.com/sumstats_flat_files/biomarkers-30840-both_sexes-irnt.tsv.bgz and https://pan-ukb-us-east-1.s3.amazonaws.com/sumstats_flat_files_tabix/biomarkers-30840-both_sexes-irnt.tsv.bgz.tbi
- Plink association testing best practices: https://www.cog-genomics.org/plink/2.0/assoc#glm
- PyMOL: https://pymol.org/2/
- rhdf5: https://www.bioconductor.org/packages/release/bioc/html/rhdf5.html
- Scipy.stats: https://docs.scipy.org/doc/scipy/reference/stats.html
- SNP-STR reference panel: https://gymreklab.com/2018/03/05/snpstr_imputation.html
- Statsmodels: https://www.statsmodels.org/stable/index.html
- UKB Data Showcase Search Page: https://biobank.ctsu.ox.ac.uk/crystal/search.cgi

Acknowledgments

Research reported in this publication was supported in part by NIH/NHGRI grants R01HG010885 (M.G. and A.G.) and 1RM1HG011558 (M.G.). This research has been conducted using the UK Biobank Resource under application number 46122. We thank R. Wachs for helping with illustrations. We also thank K. Frazer and M. D'Antonio for helpful discussions and comments.

GTEx Project: The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health (commonfund.nih.gov/GTEx). Additional funds were provided by the NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. Donors were enrolled at Biospecimen Source Sites funded by NCI\Leidos Biomedical Research, Inc. subcontracts to the National Disease Research Interchange (10XS170), GTEx Project March 5, 2014 version Page 5 of 8 Roswell Park Cancer Institute (10XS171), and Science Care, Inc. (X10S172). The Laboratory, Data Analysis, and Coordinating Center (LDACC) was funded through a contract (HHSN268201000029C) to the The Broad Institute, Inc. Biorepository

operations were funded through a Leidos Biomedical Research, Inc. subcontract to Van Andel Research Institute (10ST1035). Additional data repository and project management were provided by Leidos Biomedical Research, Inc. (HHSN261200800001E). The Brain Bank was supported supplements to University of Miami grant DA006227. Statistical Methods development grants were made to the University of Geneva (MH090941 & MH101814), the University of Chicago (MH090951,MH090937, MH101825, & MH101820), the University of North Carolina - Chapel Hill (MH090936), North Carolina State University (MH101819),Harvard University (MH090948), Stanford University (MH101782), Washington University (MH101810), and to the University of Pennsylvania (MH101822). The datasets used for the analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession numbers phs000424.v7.p2 and phs000424.v8.p2.

Author contributions

J.M. led, designed and performed the analyses and wrote the manuscript. S.F. helped oversee physiological interpretation of individual signals. Y.L. performed expression and methylation analyses of the GTEx data. X.Z. performed analyses of protein-coding STRs with AlphaFold. A.M. assisted with analysis of the *APOB* locus. A.G. and M.G. conceived the study, supervised analyses, and wrote the manuscript. All authors read and approved this manuscript.

Competing interests

The authors have no competing financial interests to declare.

Code availability

The associaTR tool has been published as part of the TRTools[73] package and tool-suite (https://trtools.readthedocs.io/). Code for performing most of the analyses and generating most of the figures in this paper can be found at https://github.com/LiterallyUniqueLogin/ukbiobank_strs/

Data Availability

Full results from our analyses can be found at URL. We are in the process of uploading imputed STR calls to the UK Biobank.

1335 **References cited**

1336 1. Visscher, P. M. *et al.* 10 Years of GWAS Discovery: Biology, Function, and Translation. *Am.*
1337 *J. Hum. Genet.* **101**, 5–22 (2017).
1338 2. Mukamel, R. E. *et al.* Protein-coding repeat polymorphisms strongly shape diverse human
1339 phenotypes. *Science* **373**, 1499–1505 (2021).
1340 3. Grünewald, T. G. P. *et al.* Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility
1341 gene EGR2 via a GGAA microsatellite. *Nat. Genet.* **47**, 1073–1078 (2015).
1342 4. Sekar, A. *et al.* Schizophrenia risk from complex variation of complement component 4.
1343 *Nature* **530**, 177–183 (2016).
1344 5. Boettger, L. M. *et al.* Recurring exon deletions in the HP (haptoglobin) gene contribute to
1345 lower blood cholesterol levels. *Nat. Genet.* **48**, 359–366 (2016).
1346 6. Willems, T. *et al.* Genome-wide profiling of heritable and de novo STR variations. *Nat.*
1347 *Methods* **14**, 590–592 (2017).
1348 7. Ellegren, H. Microsatellites: simple sequences with complex evolution. *Nat. Rev. Genet.* **5**,
1349 435–445 (2004).
1350 8. Sun, J. X. *et al.* A direct characterization of human mutation based on microsatellites. *Nat.*
1351 *Genet.* **44**, 1161–1165 (2012).
1352 9. Lynch, M. Rate, molecular spectrum, and consequences of human mutation. *Proc. Natl.*
1353 *Acad. Sci.* **107**, 961–968 (2010).
1354 10. Mirkin, S. M. Expandable DNA repeats and human disease. *Nature* **447**, 932–940
1355 (2007).
1356 11. Malik, I., Kelley, C. P., Wang, E. T. & Todd, P. K. Molecular mechanisms underlying
1357 nucleotide repeat expansion disorders. *Nat. Rev. Mol. Cell Biol.* **22**, 589–607 (2021).
1358 12. Quilez, J. *et al.* Polymorphic tandem repeats within gene promoters act as modifiers of
1359 gene expression and DNA methylation in humans. *Nucleic Acids Res.* **44**, 3750–3762 (2016).

1360 13. Fotsing, S. F. *et al.* The impact of short tandem repeat variation on gene expression.
1361 *Nat. Genet.* **51**, 1652–1659 (2019).
1362 14. Tw, H., Jd, G., Ce, Y. & Gr, C. A variable dinucleotide repeat in the CFTR gene
1363 contributes to phenotype diversity by forming RNA secondary structures that alter splicing.
1364 *Proc. Natl. Acad. Sci. U. S. A.* **101**, (2004).
1365 15. Hui, J., Stangl, K., Lane, W. S. & Bindereif, A. HnRNP L stimulates splicing of the eNOS
1366 gene by binding to variable-length CA repeats. *Nat. Struct. Biol.* **10**, 33–37 (2003).
1367 16. Vinces, M. D., Legendre, M., Caldara, M., Hagihara, M. & Verstrepen, K. J. Unstable
1368 tandem repeats in promoters confer transcriptional evolvability. *Science* **324**, 1213–1216
1369 (2009).
1370 17. Martin-Trujillo, A., Garg, P., Patel, N., Jadhav, B. & Sharp, A. J. Genome-wide
1371 evaluation of the effect of short tandem repeat variation on local DNA methylation. *Genome*
1372 *Res.* **33**, 184–196 (2023).
1373 18. Murat, P., Guilbaud, G. & Sale, J. E. DNA polymerase stalling at structured DNA
1374 constrains the expansion of short tandem repeats. *Genome Biol.* **21**, 209 (2020).
1375 19. Rothenburg, S., Koch-Nolte, F., Rich, A. & Haag, F. A polymorphic dinucleotide repeat in
1376 the rat nucleolin gene forms Z-DNA and inhibits promoter activity. *Proc. Natl. Acad. Sci.* **98**,
1377 8985–8990 (2001).
1378 20. Freudenreich, C. H. R-loops: Targets for Nuclease Cleavage and Repeat Instability.
1379 *Curr. Genet.* **64**, 789–794 (2018).
1380 21. Niehrs, C. & Luke, B. Regulatory R-loops as facilitators of gene expression and genome
1381 stability. *Nat. Rev. Mol. Cell Biol.* **21**, 167–178 (2020).
1382 22. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat.*
1383 *Genet.* **48**, 1279–1283 (2016).
1384 23. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74
1385 (2015).

1386 24. Huang, J. *et al.* Improved imputation of low-frequency and rare variants using the UK10K
1387 haplotype reference panel. *Nat. Commun.* **6**, 8111 (2015).
1388 25. Dashnow, H. *et al.* STRetch: detecting and discovering pathogenic short tandem repeat
1389 expansions. *Genome Biol.* **19**, 1–13 (2018).
1390 26. Mousavi, N., Shleizer-Burko, S., Yanicky, R. & Gymrek, M. Profiling the genome-wide
1391 landscape of tandem repeat expansions. *Nucleic Acids Res.* **47**, e90 (2019).
1392 27. Dolzhenko, E. *et al.* ExpansionHunter: a sequence-graph-based tool to analyze variation
1393 in short tandem repeat regions. *Bioinformatics* **35**, 4754–4756 (2019).
1394 28. Tang, H. *et al.* Profiling of Short-Tandem-Repeat Disease Alleles in 12,632 Human
1395 Whole Genomes. *Am. J. Hum. Genet.* **101**, 700–715 (2017).
1396 29. Tankard, R. M. *et al.* Detecting Expansions of Tandem Repeats in Cohorts Sequenced
1397 with Short-Read Sequencing Data. *Am. J. Hum. Genet.* **103**, 858–873 (2018).
1398 30. Saini, S., Mitra, I., Mousavi, N., Fotsing, S. F. & Gymrek, M. A reference haplotype panel
1399 for genome-wide imputation of short tandem repeats. *Nat. Commun.* **9**, 4397 (2018).
1400 31. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
1401 *Nature* **562**, 203–209 (2018).
1402 32. Browning, B. L., Zhou, Y. & Browning, S. R. A One-Penny Imputed Genome from Next-
1403 Generation Reference Panels. *Am. J. Hum. Genet.* **103**, 338–348 (2018).
1404 33. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer
1405 datasets. *GigaScience* **4**, (2015).
1406 34. Pan-UKB team. Pan-ancestry genetic analysis of the UK Biobank.
1407 https://pan.ukbb.broadinstitute.org/ (2020).
1408 35. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable
1409 selection in regression, with application to genetic fine mapping. *J. R. Stat. Soc. Ser. B Stat.*
1410 *Methodol.* **82**, 1273–1300 (2020).

1411 36. Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from
1412 genome-wide association studies. *Bioinformatics* **32**, 1493–1501 (2016).
1413 37. THE GTEX CONSORTIUM. The GTEx Consortium atlas of genetic regulatory effects
1414 across human tissues. *Science* **369**, 1318–1330 (2020).
1415 38. Berberich, A. J. & Hegele, R. A. A Modern Approach to Dyslipidemia. *Endocr. Rev.*
1416 bnab037 (2021) doi:10.1210/endrev/bnab037.
1417 39. Boerwinkle, E. & Chan, L. A three codon insertion/deletion polymorphism in the signal
1418 peptide region of the human apolipoprotein B (APOB) gene directly typed by the polymerase
1419 chain reaction. *Nucleic Acids Res.* **17**, 4003 (1989).
1420 40. Niu, C. *et al.* Associations of the APOB rs693 and rs17240441 polymorphisms with
1421 plasma APOB and lipid levels: a meta-analysis. *Lipids Health Dis.* **16**, 166 (2017).
1422 41. Hui, J. *et al.* Intronic CA-repeat and CA-rich elements: a new class of regulators of
1423 mammalian alternative splicing. *EMBO J.* **24**, 1988–1998 (2005).
1424 42. Huang, Y. *et al.* Mediator complex regulates alternative mRNA processing via the
1425 MED23 subunit. *Mol. Cell* **45**, 459–469 (2012).
1426 43. Sutcliffe, J. S. *et al.* DNA methylation represses FMR-1 transcription in fragile X
1427 syndrome. *Hum. Mol. Genet.* **1**, 397–400 (1992).
1428 44. Garg, P. *et al.* A Survey of Rare Epigenetic Variation in 23,116 Human Genomes
1429 Identifies Disease-Relevant Epivariations and CGG Expansions. *Am. J. Hum. Genet.* **107**,
1430 654–669 (2020).
1431 45. Saur, S. J., Sangkhae, V., Geddis, A. E., Kaushansky, K. & Hitchcock, I. S.
1432 Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. *Blood* **115**, 1254–1263
1433 (2010).
1434 46. Plo, I. *et al.* Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting
1435 Megakaryopoiesis. *Front. Endocrinol.* **8**, 234 (2017).

1436 47. Kaushansky, K. *et al.* Promotion of megakaryocyte progenitor expansion and
1437 differentiation by the c-Mpl ligand thrombopoietin. *Nature* **369**, 568–571 (1994).
1438 48. Märklin, M. *et al.* C-Cbl regulates c-MPL receptor trafficking and its internalization. *J.*
1439 *Cell. Mol. Med.* **24**, 12491–12503 (2020).
1440 49. Lappalainen, T. *et al.* Transcriptome and genome sequencing uncovers functional
1441 variation in humans. *Nature* **501**, 506–511 (2013).
1442 50. Shinjyo, T. *et al.* Downregulation of Bim, a Proapoptotic Relative of Bcl-2, Is a Pivotal
1443 Step in Cytokine-Initiated Survival Signaling in Murine Hematopoietic Progenitors. *Mol. Cell.*
1444 *Biol.* **21**, 854–864 (2001).
1445 51. Kotzin, J. J. *et al.* The long non-coding RNA Morrbid regulates Bim and short-lived
1446 myeloid cell lifespan. *Nature* **537**, 239–243 (2016).
1447 52. Bouillet, P. *et al.* Proapoptotic Bcl-2 Relative Bim Required for Certain Apoptotic
1448 Responses, Leukocyte Homeostasis, and to Preclude Autoimmunity. *Science* **286**, 1735–
1449 1738 (1999).
1450 53. Draviam, V. M. *et al.* A functional genomic screen identifies a role for TAO1 kinase in
1451 spindle-checkpoint signalling. *Nat. Cell Biol.* **9**, 556–564 (2007).
1452 54. Favier, R. & Raslova, H. Progress in understanding the diagnosis and molecular
1453 genetics of macrothrombocytopenias. *Br. J. Haematol.* **170**, 626–639 (2015).
1454 55. Azad, P., Villafuerte, F. C., Bermudez, D., Patel, G. & Haddad, G. G. Protective role of
1455 estrogen against excessive erythrocytosis in Monge's disease. *Exp. Mol. Med.* **53**, 125–135
1456 (2021).
1457 56. Mukundan, H., Resta, T. C. & Kanagy, N. L. 17β-Estradiol decreases hypoxic induction
1458 of erythropoietin gene expression. *Am. J. Physiol.-Regul. Integr. Comp. Physiol.* **283**, R496–
1459 R504 (2002).
1460 57. Krusche, P. *et al.* Best practices for benchmarking germline small-variant calls in human
1461 genomes. *Nat. Biotechnol.* **37**, 555–560 (2019).

1462 58. Hannan, A. J. Tandem repeat polymorphisms: modulators of disease susceptibility and
1463 candidates for ‘missing heritability’. *Trends Genet.* **26**, 59–65 (2010).
1464 59. Press, M. O., Carlson, K. D. & Queitsch, C. The overdue promise of short tandem repeat
1465 variation for heritability. *Trends Genet.* **30**, 504–512 (2014).
1466 60. D’Antonio, M. *et al.* Systematic genetic analysis of the MHC region reveals mechanistic
1467 underpinnings of HLA type associations with disease. *eLife* **8**, e48476 (2019).
1468 61. Chiang, C. *et al.* The impact of structural variation on human gene expression. *Nat.*
1469 *Genet.* **49**, 692–699 (2017).
1470 62. Halldorsson, B. V. *et al.* The sequences of 150,119 genomes in the UK Biobank. *Nature*
1471 **607**, 732–740 (2022).
1472 63. Foix, Anna & Blachly, James. pyEGA3: EGA download client. (2021).
1473 64. O’Connell, J. *et al.* Haplotype estimation for biobank-scale data sets. *Nat. Genet.* **48**,
1474 817–820 (2016).
1475 65. Horta, D. bgen-reader: Bgen file format reader.
1476 66. Staples, J., Nickerson, D. A. & Below, J. E. Utilizing Graph Theory to Select the Largest
1477 Set of Unrelated Individuals for Genetic Analysis. *Genet. Epidemiol.* **37**, 136–141 (2013).
1478 67. Beasley, T. M., Erickson, S. & Allison, D. B. Rank-Based Inverse Normal
1479 Transformations are Increasingly Used, But are They Merited? *Behav. Genet.* **39**, 580–595
1480 (2009).
1481 68. Bishara, A. J. & Hittner, J. B. Testing the significance of a correlation with nonnormal
1482 data: comparison of Pearson, Spearman, transformation, and resampling approaches.
1483 *Psychol. Methods* **17**, 399–417 (2012).
1484 69. Zwiener, I., Frisch, B. & Binder, H. Transforming RNA-Seq Data to Improve the
1485 Performance of Prognostic Gene Signatures. *PLOS ONE* **9**, e85150 (2014).
1486 70. Bishara, A. J. & Hittner, J. B. Reducing Bias and Error in the Correlation Coefficient Due
1487 to Nonnormality. *Educ. Psychol. Meas.* **75**, 785–804 (2015).

1488 71. Auer, P. L., Reiner, A. P. & Leal, S. M. The effect of phenotypic outliers and non-
1489 normality on rare-variant association testing. *Eur. J. Hum. Genet.* **24**, 1188–1194 (2016).
1490 72. Pedersen, B. cyvcf2: fast vcf parsing with cython + htslib.
1491 73. Mousavi, N. *et al.* TRTools: a toolkit for genome-wide analysis of tandem repeats.
1492 *Bioinformatics* **37**, 731–733 (2021).
1493 74. Zheng, J., Li, Y., Abecasis, G. R. & Scheet, P. A Comparison of Approaches to Account
1494 for Uncertainty in Analysis of Imputed Genotypes. *Genet. Epidemiol.* **35**, 102–110 (2011).
1495 75. Frankish, A. *et al.* GENCODE reference annotation for the human and mouse genomes.
1496 *Nucleic Acids Res.* **47**, D766–D773 (2019).
1497 76. Dunham, I. *et al.* An integrated encyclopedia of DNA elements in the human genome.
1498 *Nature* **489**, 57–74 (2012).
1499 77. Kent, W. J. *et al.* The Human Genome Browser at UCSC. *Genome Res.* **12**, 996–1006
1500 (2002).
1501 78. Robinson, J. T. *et al.* Integrative genomics viewer. *Nat. Biotechnol.* **29**, 24–26 (2011).
1502 79. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic
1503 features. *Bioinformatics* **26**, 841–842 (2010).
1504 80. Karolchik, D. *et al.* The UCSC Table Browser data retrieval tool. *Nucleic Acids Res.* **32**,
1505 D493–D496 (2004).
1506 81. Price, A. L. *et al.* Principal components analysis corrects for stratification in genome-
1507 wide association studies. *Nat. Genet.* **38**, 904–909 (2006).
1508 82. Stegle, O., Parts, L., Piipari, M., Winn, J. & Durbin, R. Using probabilistic estimation of
1509 expression residuals (PEER) to obtain increased power and interpretability of gene
1510 expression analyses. *Nat. Protoc.* **7**, 500–507 (2012).
1511 83. Schafer, S. *et al.* Alternative Splicing Signatures in RNA-seq Data: Percent Spliced in
1512 (PSI). *Curr. Protoc. Hum. Genet.* **87**, 11.16.1-11.16.14 (2015).

1513 84. Oliva, M. *et al.* DNA methylation QTL mapping across diverse human tissues provides
1514 molecular links between genetic variation and complex traits. *Nat. Genet.* **55**, 112–122
1515 (2023).
1516 85. Byrska-Bishop, M. *et al.* High coverage whole genome sequencing of the expanded
1517 1000 Genomes Project cohort including 602 trios. 2021.02.06.430068 Preprint at
1518 https://doi.org/10.1101/2021.02.06.430068 (2021).
1519 86. Patterson, N., Price, A. L. & Reich, D. Population Structure and Eigenanalysis. *PLOS*
1520 *Genet.* **2**, e190 (2006).
1521